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ABSTRACT
There are many potential clinical applications for localized drug delivery and sensing
systems, such as cancer, vaccinations, pain management, and hormone therapy. Localized drug
delivery systems reduce the amount of drug required for a therapeutic effect and the severity of
side effects. Delivery of multiple chemicals has been demonstrated previously from a polymeric
microreservoir device. This dime-sized device contains small reservoirs loaded with drug and
separated from the outside environment by a degradable polymer membrane. This device was
modified to allow minimally invasive implantation with a large-bore needle and has
demonstrated in vitro pulsatile release of a model compound after a mock implantation step. A
biodegradable sealing method was developed for the polymeric microreservoir device, which
makes the device completely resorbable and eliminates the surgical removal step needed with a
non-resorbable device.
Localized sensing systems will allow early detection of diseases and provide a tool for
developing personalized treatment programs. The polymer microchip platform has been
combined with magnetic relaxation switch (MRSw) nanoparticle sensors to create an in vivo
sensing device. MRSw are magnetic nanoparticles (iron oxide core, crosslinked dextran shell)
that can detect a variety of analytes. MRSw are kept in the device by a molecular weight cut-off
(MWCO) membrane which allows analytes free access to the nanoparticle sensors. The MRSw
aggregate in the presence of the analyte they were designed to detect and this aggregation causes
a decrease in the transverse relaxation time (T2), which can be detected with magnetic resonance
imaging (MRI) or nuclear magnetic resonance relaxometry. In vitro sensing experiments were
used to optimize the device design and characterize its performance. In vivo device-based
sensing of hCG, a soluble biomarker that is elevated in testicular and ovarian cancer, has been
demonstrated. Cell lines secreting hCG were used to produce ectopic tumors in nude mice. The
sensing device was implanted and magnetic resonance imaging (MRI) quantified a T2 decrease in
mice with tumors compared to control mice (no tumors). This device may be the first continuous
monitoring device for cancer that can be implanted at the tumor site and demonstrates feasibility
of MRSw measurements in vivo.
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Thesis Committee: Professor Michael J. Cima (MIT)
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Chapter 1 Introduction and Background
There are many potential clinical applications for localized drug delivery and sensing
systems, such as vaccinations, cancer therapy, pain management, and hormone therapy.
Localized drug delivery systems reduce both the amount of drug required for a therapeutic effect
and the severity of side effects associated with treatment. Localized sensing systems will allow
early detection of diseases and provide a tool for developing personalized treatment programs.
Cancer, for examples, is diagnosed by histologic examination of tissue samples often taken by
biopsy' " . These invasive procedures offer an opportunity to leave behind a device to locally
monitor tumor biomarker, chemotherapeutic agent, and tumor metabolite concentrations. The
ability to repeatedly sample the local environment, in addition to sampling easily accessible
fluids, could improve both early detection of metastasis5 '6 and personalized therapy7' 8.
1.1 Microchip for Localized Drug Delivery
One example of a drug that would benefit from localized delivery is carmustine (BCNU),
a small, hydrophobic chemotherapeutic agent that is used in the treatment of malignant brain
tumors. Although BCNU is commonly administered intravenously, the poor permeability of the
blood-brain barrier requires large systemic doses in order to achieve therapeutic drug levels in
the brain. The large systemic BCNU concentrations can induce harmful side effects in the liver,
kidneys and spleen. Localized delivery systems have been developed to reduce the amount of
BCNU required and to reduce the severity of these side effects9'10 . The Gliadel® Wafer, a
biodegradable polymeric delivery system for the continuous release of BCNU, was approved by
the FDA in 1996 for recurrent glioblastoma multiforme (GBM) brain tumors, and in 2003 as
initial therapy for GBM brain tumors. The wafer consists of a compressed polyanhydride (PA)
matrix that is impregnated with BCNU. It is implanted at the tumor site during surgery for tumor
resection and delivers BCNU directly to the brain tumor site9. In addition to BCNU, local
delivery of interleukin-2 (IL-2) has recently shown improved survival in animal brain tumor
models by eliciting an antitumor immune response". In vivo studies using an animal glioma
model have shown that combining BCNU with IL-2 has a synergistic therapeutic effect, and is
able to significantly improve survival' 2-14. In the most efficacious therapy, IL-2 microspheres
were first implanted at the intracranial tumor site, followed five days later by implantation of
BCNU-containing polymer implants1 4. For this complex therapy, a single device that could
deliver both IL-2 and BCNU with precise control over the temporal release profile of each drug
would be desired. In comparison, existing therapies would require multiple surgeries for
implantation and would likely not be capable of the same level of control over the release
profiles.
Local delivery of multiple chemicals has been demonstrated from a silicon microchip' 5
(active device, Figure 1-1a and b) and a resorbable polymeric microchip 16 (passive device,
Figure 1-1c and d). The microchips contain small reservoirs that are loaded with drug and
separated from the outside environment by a membrane. In the active device, the membrane is a
thin layer of gold. When drug needs to be released from a reservoir, a voltage is applied which
causes electrochemical dissolution of the gold anode membrane 15'17 . The passive microchip
contains degradable polymer membranes. The composition, molecular weight, and thickness of
the membrane determine when the drug depot will be released from the reservoir' 6 . These
microchips are unique because they contain no moving parts and are capable of delivering drugs
in the solid, liquid, or gel state. Also, the microchip is a significant improvement over
commercially available polymeric delivery systems because it is not limited to a continuous
release profile. There are many cases where pulsatile, not continuous, delivery of a drug is
preferred. Another benefit of the microchip is that the drug depot is protected from the outside
environment before release.
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Figure 1-1. Schematic of two types of drug delivery microchip devices. a) Active, silicon device, b) Close-up of
single reservoir in active device15 . c) Passive, polymeric device, d) Close-up of single reservoir in passivedevice1 .
Both the active and the passive microchip have demonstrated in vitro pulsatile release of
multiple compounds, such as sodium fluorescein, dextran, heparin, and human growth
hormone15, '6 . In addition, both devices have shown controlled, pulsatile release of certain
chemicals in vivo (using a rat model). The passive microchip has demonstrated controlled in vivo
release of mannitol' 8 and the active microchip has demonstrated controlled in vivo release of
sodium fluorescein, mannitol and BCNU 19. However, the microchips are not limited to just
pulsatile release of chemicals. The release profile from a microchip is essentially unlimited, since
each reservoir can be opened independently from the other reservoirs.
1.2 Magnetic Resonance Switch (MRSw) Nanoparticle Sensors
MRSw are magnetic nanoparticles (iron oxide core, crosslinked dextran shell (CLIO))
that can detect a variety of analytes2 0. MRSw have previously been functionalized to detect
peptides, oligonucleotides, nucleic acids, receptor ligands, proteins, small molecules and
antibodies 21-26. The lower limit of detection and working concentration range is determined by
the nanoparticle design. In some cases the lower limit of detection is in the low femtomole
range24 . These MRSw have been used extensively for in vitro agglutination assays where the
MRSw and analyte solutions are mixed together. Continuous monitoring of glucose with MRSw
contained within a dialysis membrane has also been demonstrated in vitro25. The MRSw
aggregate in the presence of the analyte they were designed to detect and this aggregation causes
a decrease in the transverse relaxation time (T2). Magnetic resonance imaging (MRI) or nuclear
magnetic resonance (NMR) relaxometry can be used to quantify the T2 of the MRSw and
determine if aggregation has occurred 24,27,28 .
Figure 1-2 is a schematic of MRSw used to detect hCG-b, a soluble biomarker (~23 kDa)
that is elevated in testicular and ovarian cancer2 9-32 . Serum concentrations up to 16 pg/ml were
reported in one condition, persistent trophoblastic disease, whereas they are usually less than
0.005 pg/ml in normal men and women 33. These MRSw have been previously shown to detect
0.5 to 5 tg/mL hCG-p26. hCG is a monovalent analyte, so two populations of MRSw were
prepared (C95 and C97), each conjugated with a different monoclonal antibody for hCG-b. HCG
or hCG-b, when present, creates a bridge between C95 and C97, similar to an ELISA sandwhich.
There is some variability in the average number of antibodies conjugated to the MRSw (valency)
each time a batch of nanoparticles are functionalized 26. Aggregation occurs when both types of
MRSw are present with either the hCG-b subunit or the hCG dimer. The MRSw are initially
dispersed (high T2), whereas addition of the analyte (hCG-b or hCG) causes the MRSw to
aggregate in clusters. The aggregated MRSw are more efficient at dephasing the spins of
surrounding water protons, which is seen as a decrease in the T22 6
Figure 1-2. Schematic of MRSw aggregation with hCG-b. When hCG is present it causes aggregation of the
two MRSw populations. The aggregated MRSw are more efficient at dephasing the spins of the surrounding
water protons, which is seen as a decrease in T2, the transverse relaxation time.
The optimum range of operation, in terms of analyte and MRSw concentration, depends
on the specific analyte and MRSw being used 26,28 ,3 4 . The signal from the aggregated particles is
masked by the signal from the many un-aggregated particles when there is too little analyte
present, and there is no detectable decrease in T2. Bridges are formed that network together
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multiple MRSw resulting in aggregates that can be detected by a decrease in T2 when the relative
concentrations of analyte and MRSw are in the correct range. Every receptor on the surface of
the MRSw is filled with an analyte molecule when too much analyte is present. Aggregates are
not able to form because there are no open binding sites to create bridges between particles. This
is a common phenomena in agglutination assays, and is called the prozone or hook effect2 6,28,34-
36. Insolubility and precipitation of aggregates will also occur if the network of aggregated
MRSw grows too large26 ,28. Insolubility and precipitation of aggregates is more common with
high valency MRSw (i.e. 4 or more Ab per particle) when detecting hCG, but can also occur with
lower valency MRSw that are combined with high hCG solutions2 6. The response of MRSw to
hCG is studied for each batch to determine the relative MRSw and hCG concentrations that lead
to stable aggregates.
1.3 Implantable Device for Localized Sensing
The main objective of my thesis is to combine the polymer microchip drug delivery
platform with MRSw nanoparticle sensors to create an in vivo sensing device. This sensing
device could be used in a variety of applications, but this thesis will focus on applications in the
detection and treatment of cancer. Figure 1-3 is a generic schematic of a proposed sensing
device. MRSw are kept in the reservoirs by a molecular weight cut-off (MWCO) membrane.
The MWCO membrane allows analytes free access to the nanoparticle sensors but does not allow
the MRSw to diffuse out of the wells. Erodible timing films can also be added to control when
each well is exposed to the sensing environment. Packaging the MRSw in our device addresses
two key challenges related to using the MRSw in vivo: possible immune response to the protein
modified nanoparticles, and T2 fluctuations due to changes in MRSw concentration. The semi-
permeable membrane exposes the MRSw to analytes in the local environment but prevents the
MRSw from invoking a possible immune response. The rigid device substrate provides a
constant-volume reservoir so the concentration of MRSw remains constant. This allows any T2
changes to be attributed solely to aggregation of the nanoparticles28
Figure 1-3. Schematic of proposed sensing device. MRSw are contained in reservoirs in the device substrate.
Molecular weight cut-off (MWCO) membranes keep the MRSw in the reservoirs but allow analytes to diffuse
into the reservoirs and interact with the MRSw. Each reservoir could be filled with MRSw designed to detect
a different analyte. Resorbable timing films could be added to each reservoir to initially isolate the MRSw
from the in vivo environment.
Technologies for early detection of cancer through cancer-associated biomarkers will
have far-reaching impact on cancer research and clinical care37'38 . The ability to monitor soluble
cancer markers locally in real-time could improve sensitivity and allow for detection of cancer
cells before they are recognizable by standard MRI and could also provide information on the
delivery of current or experimental drugs to tumors. Current clinical methods of measuring
cancer markers or drug concentrations are limited to sampling easily accessible fluids (such as
blood) or surgical procedures38 -40 . Surgical procedures allow sampling of the local tumor
environment, where concentrations of cancer biomarkers are significantly higher than serum
levels41,42 . These invasive sampling techniques, however, are not feasible for continuous
monitoring and widespread clinical use. This thesis describes a sensing device that could be
made small enough to allow local minimally invasive sensing and real-time analysis of cancer-
related molecules.
1.4 Thesis Objectives
Thesis objectives pertaining to developing an in vivo sensing device (Chapter 2) are:
1. Quantify analyte diffusion through MWCO membranes (Chapter 3).
2. Characterize kinetics of MRSw aggregation (Chapter 4 and Chapter 5).
3. Perform ex vivo diffusion studies to determine if biomolecule adsorption to MWCO
membranes affects analyte diffusion (Chapter 3).
4. Perform in vivo sensing experiments (Chapter 6).
My final thesis objective is to modifying the previously developed polymer microchip for drug
delivery applications:
5. Engineer a resorbable sealing mechanism and design the passive microchip to allow
implantation through a trocar or large-bore needle (Chapter 7).
Chapter 2 Sensor Device Fabrication
2.1 Summary
The most reliable design for the sensing device is a cup-shaped device made from HDPE.
Double-sided pressure-sensitive adhesive is used to seal a polycarbonate membrane to the device
substrate. MRSw are added to the reservoir through a filling port on the back of the device which
is then sealed with pressure sensitive adhesive. This device design has proven to be very reliable
for the in vitro and in vivo studies carried out to date. The device reservoir, 5 mm in diameter and
2.5 mm deep, allows the T2 to be quantified using either MRI or single-sided MR.
2.2 Introduction
There are several key elements in the sensor device fabrication and design. The substrate
material must be magnetically inert, biocompatible, and able to create a leak proof seal with the
MWCO membrane. The device must be filled with the MRSw solution and sealed in a manner
that minimizes air bubbles within the reservoir and prevents the MRSw from leaking out of the
back of the device. This sealing method cannot employ high temperatures since the MRSw are
thermally sensitive. Devices used in in vivo sensing experiments will experience mechanical
stresses while implanted and the device substrate and membrane must be able to withstand these
stresses without failure of the membrane-substrate or substrate-sealing layer bonds. A cup-
shaped device has proven to be the most reliable format for in vitro and in vivo sensing
applications. The device substrate is made from high density polyethylene (HDPE) and a
pressure-sensitive adhesive is used to seal the polycarbonate membrane to the substrate. In vitro
leak tests for several weeks at 370 C have shown that the MRSw are well contained within the
reservoirs.
2.3 Materials and Methods
2.3.1 In vitro devices for MRI detection
Polydimethylsiloxane (PDMS) was chosen as the substrate material for the first
generation in vitro sensing devices because it is magnetically inert, biocompatible and easily
fabricated into arrays of wells. PDMS (Sylgard® 184, Dow Coming, Midland, MI) was prepared
according to manufacturer directions in a custom-machined aluminum mold. The mold was
placed under a vacuum for at least one hour to remove air bubbles and then cured in a 60C oven
overnight. The devices are 3 mm thick with 2 mm square reservoirs and can be cut into single-
reservoir or multi-reservoir devices.
Membrane bonding to PDMS was tested by filling a reservoir with a concentrated non-
functionalized MRSw solution (8.43 mg Fe/mL) then applying a thin layer of silicone adhesive
(Loctite®, Henkel Loctite Corp, Rocky Hill, CT) between the substrate and MWCO membrane.
Polycarbonate (SPI Supplies, West Chester, PA), polyethersulfone (Millipore, Billerica, MA),
aluminum oxide (SPI Supplies, West Chester, PA) and nitrocellulose (Millipore, Billerica, MA)
were tested. The adhesive was cured at room temperature for at least 24 hours and then the
devices were placed in water at 370 C for up to one week. Optical microscopy was used to
visually inspect for gross failure of the substrate-MWCO membrane bond.
The ability of polycarbonate membranes (10 nm pores, 6x10 8 pores/cm 2, SPI Supplies,
West Chester, PA) to bond to PDMS was also tested quantitatively. The PDMS substrate was
turned on its side and cut to turn the square reservoirs into through holes. The polycarbonate
membrane was adhered to the substrate with a thin layer of silicone adhesive. The adhesive was
cured at room temperature for 12 - 24 hours and then the reservoir was filled with a solution of
functionalized MRSw (12 pL, 2 - 16 gg Fe/mL). The back of the reservoir was sealed with a
pressure sensitive adhesive (Ideal 9144, American Biltrite, Lowell, MA) and the devices were
placed in a solution of phosphate buffered saline pH 7.4 with 1 mg/mL bovine serum albumin
and 1% penicillin-streptomycin (PBS-BSA-PS) at 370 C. The T2 of the MRSw in the reservoir
was quantified by MRI 3 or 5 hours after being placed in the PBS-BSA-PS bath and again 24
hours later. An increase in T2 at the second time point would indicate leakage of the MRSw,
since T2 increases as MRSw concentration decreases 43
2.3.2 In vitro devices for single-sided MR detection
The substrate material and reservoir size were modified to allow for detection with the
single-sided MR, which has lower resolution than MRI. Low density polyethylene (LDPE) and
high density polyethylene (HDPE), which are more solid polymers than PDMS, were used for
the device substrate. These polymers have a lower T2,eff than PDMS, so even if the device
substrate is within the sensitive volume of the single-sided MR, it will not interfere with
quantifying the T2,eff of the MRSw solution inside the reservoir. An additional benefit with these
polymers is increased mechanical strength of the substrate.
Low density polyethylene (LDPE) was cut with cork punches into a washer-shaped
device with an inner diameter of 10 mm, outer diameter of 14 mm, and thickness of 2 mm. A
thin layer of silicone adhesive or double-sided pressure sensitive adhesive was used to adhere
polycarbonate membranes to the washer devices. The devices were filled with functionalized
MRSw (160 jiL, 8 Ig Fe/mL), sealed on the back with a pressure sensitive adhesive, and placed
in a solution of PBS-BSA-PS at room temperature. Single-sided MR was used to quantify the
T2,eff of the MRSw in each device immediately after fabrication and again after 12 - 24 hours to
confirm that the devices were not leaking.
Washer-shaped devices were also drilled from a sheet of high density polyethylene
(HDPE), with an inner diameter of 6 mm, outer diameter of 10 mm, and thickness of 3 mm.
Pressure sensitive adhesive was used to adhere the polycarbonate membrane to the HDPE
substrate. The devices were filled and sealed in the same manner as the LDPE washer devices.
2.3.3 In vitro and in vivo devices for MRI or single-sided MR detection
Devices were modified to a cup-shaped HDPE substrate to improve reliability during in
vitro and in vivo sensing experiments. Cylinders of HDPE (10 mm diameter) were cut from a 3
mm thick sheet to make the device substrate. The centers of the cylinders were drilled out to
create a cup-shaped device with a reservoir that is 5 mm in diameter and 2.5 mm deep. This
reservoir size is larger than needed for MRI detection but allows the same device to be measured
by MRI and single-sided MR. A 1.5 mm diameter hole was drilled through the bottom of the cup
as a filling port. Double-sided pressure sensitive adhesive was used to attach the polycarbonate
membrane to the top of the device. The reservoir was filled with 50 giL of MRSw solution
through the filling port and it was then sealed with pressure sensitive adhesive. The MRSw
solutions were diluted to 8 jtg Fe/mL using PBS-BSA-PS. The devices were immediately placed
in PBS-BSA-PS and kept at room temperature. Single-sided MR was used to quantify the T2,eff of
the MRSw in each device immediately after fabrication and again after 12 - 24 hours to confirm
that the devices were not leaking.
2.4 Results and Discussion
2.4.1 Devices for MRI detection
Aluminum oxide, nitrocellulose and polyethersulfone membranes exhibited gross failure
of the PDMS/membrane bond after less than one day in solution. These MWCO membranes
could be used in future devices with better substrate-adhesion properties, but were not used with
the PDMS substrate. Aluminum oxide membranes are also very brittle, so it was difficult to trim
them to the appropriate dimensions without creating cracks across the membrane. Visual
inspection of the polycarbonate membranes suggested that they were able to bond to the PDMS
substrate. Figure 2-1 shows the PDMS devices used for quantitative leak tests and in vitro
sensing with MRI detection. A concentrated MRSw solution was used for the photo to make the
reservoirs more visible. MRSw solutions at the concentrations used for leak tests and in vitro
sensing (around 8 pg Fe/mL) are colorless.
Figure 2-1. PDMS devices for in vitro sensing with MRI detection. The devices can easily be fabricated as
single or multi-well devices. A concentrated MRSw solution was put in the reservoirs to make them more
visible. Each reservoir holds 12 gL of MRSw solution 44
Figure 2-2 shows quantitative leak test results for PDMS devices with polycarbonate
membranes (10 nm pores). All devices showed no significant increase in T2 one day after being
placed in a bath of PBS, indicating that the MRSw were well contained within the reservoirs.
The devices filled with MRSw at a concentration of 2 jtg Fe/mL showed more variation in T2
than other MRSw concentrations, perhaps indicating that this iron concentration is near the
detection limit for the MRI protocol used to collect the T2 data. In vivo sensing experiments were
done with MRSw concentrations around 8 tg Fe/mL.
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Figure 2-2. Leak test results for PDMS devices with MRI for T2 detection. Polycarbonate membranes (10 nm
pores) were sealed to the device substrate with a silicone adhesive. Devices were stored in PBS at 37Cbetween the two time points. The first imaging time point was 3-5 hours after the devices were placed in PBS(blue columns) and the second was 27-29 hours after the devices were placed in PBS (green columns).
Leaking of MRSw would cause a significant increase in T2 at the second time point. Error bars represent
standard deviation (n>2 for each group).
2.4.2 Devices for MRI or single-sided MR detection
2.4.2.1 Washer devices
Figure 2-3 shows the washer devices used for in vitro sensing with single-sided MR
detection. The device on the left uses a silicone adhesive to adhere the polycarbonate membrane
E
I
to the LDPE substrate. The device on the right uses a double-sided pressure sensitive adhesive to
adhere the polycarbonate membrane to the HDPE substrate.
Figure 2-3. Washer devices used for in vitro leak tests and sensing experiments. The device on the left is an
LDPE substrate and uses a silicone adhesive to seal the polycarbonate membrane to the device substrate. The
device on the right is an HDPE substrate with double-sided pressure sensitive adhesive used to adhere the
polycarbonate membrane to the device substrate.
Figure 2-4 compares leak test results for LDPE washers with two different methods for
adhering the polycarbonate membrane (10 nm pores) to the substrate: silicone adhesive and
double-sided pressure sensitive adhesive. Two devices were tested with each method. All four
devices were sealed on the back with single-sided pressure sensitive adhesive. Figure 2-4 shows
that one of the devices made with pressure sensitive adhesive immediately began leaking when
placed in a bath of PBS-BSA-PS, as indicated by the rapid increase in T2,eff (light blue triangles).
The other three devices were able to maintain a leak proof seal until day 11, when one of the
devices made with silicone adhesive began to show an increase in T2,eff (pink circles). Previous
experiments showed that the MRSw are not able to pass through the pores of the polycarbonate
membranes (see Sections 3.3.1 and 3.4.1). The leaking of MRSw in this experiment, then, must
be from failure of either the substrate/membrane seal at the front of the device or the
substrate/pressure sensitive adhesive seal at the back of the device. The most likely failure site is
the back of the device, since this seal is done after the reservoir is filled with the MRSw solution
and some of the solution often wicks out of the reservoir during sealing.
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Figure 2-4. Leak test results for LDPE washer-shaped devices in PBS at 370C. Devices were fabricated with
either a silicone adhesive or a double-sided pressure sensitive adhesive to seal the polycarbonate membrane(10 nm pores) onto the device substrate. One device shows immediate leaking of MRSw (blue triangles). A
second device initially contains the MRSw within the reservoir, but begins leaking about twelve days later(pink circles).
2.4.2.2 Cup devices
The leak test results shown in Figure 2-4 (1 out of 4 devices immediately leaks MRSw)
were common anytime washer-shaped devices were used in a leak test or sensing experiment.
Cup-shaped devices were fabricated in an attempt to decrease the number of devices that began
leaking MRSw immediately after being placed in PBS. Figure 2-5 is a picture of a cup-shaped
device with double-sided pressure sensitive adhesive used to seal a polycarbonate membrane to
the HDPE substrate. The membrane is first attached to the top of the reservoir and then the
device is turned over and the reservoir filled with MRSw solution through the small hole in the
back. Single-sided pressure sensitive adhesive is used to seal the filling hole.
or
Figure 2-5. Cup device for in vitro and in vivo sensing experiments with single-sided MR or MRI detection.
These devices are made from an HDPE substrate and use double-sided pressure sensitive adhesive to attach
the polycarbonate membrane to the substrate. The small hole in the bottom of the cup is a filling port which
is sealed with pressure sensitive adhesive after filling the reservoir with the MRSw solution..
Figure 2-6 shows leak test results for four cup-shaped HDPE devices with polycarbonate
(10 nm pore) membranes. All four of the devices maintained a constant T2,eff while in PBS at
370C for over 12 days. Cup-shaped devices were always tested for leaks before being used in an
in vitro or in vivo sensing experiment, but no cup-shaped device ever showed an immediate
MRSw leak. This suggests that the immediate leaks seen with washer-shaped devices were
probably from failure of the seal at the back of the device. The larger surface area for sealing on
the back of the cup devices eliminated this source of device failure.
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Figure 2-6. Leak test results for four HDPE cup-shaped devices in PBS at 370 C. Devices were made with
polycarbonate membranes (10 nm pores) that were sealed to the device substrate with double-sided pressure
sensitive adhesive. Single-sided MR was used to quantify the T2,ff in each device. Error bars represent 95%
confidence limits in the fit to determine T2,eff.
2.5 Conclusion
Several different device designs were made and tested. The most reliable design is a cup-
shaped device made from HDPE, with a 5 mm diameter and 2.5 mm deep reservoir. Double-
sided pressure-sensitive adhesive is used to seal a polycarbonate membrane to the device
substrate. MRSw are added to the reservoir through a filling port on the back of the device which
is then sealed with pressure sensitive adhesive. This device design has proven to be very reliable
for the in vitro and in vivo studies carried out to date. The double-sided pressure sensitive
adhesive used to seal the MWCO membrane to the device substrate, however, may not be able to
create a leak proof seal in longer term sensing experiments. A mechanical means of attaching the
MWCO membrane to the device substrate, such as two plastic pieces that are machined to fit
snugly together while holding the membrane in place between them, may improve the long term
reliability of the device.
Chapter 3 Characterization of MWCO Membranes
3.1 Summary
Several commercially available membranes are able to retain the MRSw while allowing
analyte diffusion. Apparent permeability values for hCG (38 kDa) and dextran (40, 70 and 500
kDa) with polycarbonate membranes (10 nm pores) suggest that for the conditions studied,
diffusion is influenced more by the charge and conformation of the analyte rather than the
molecular weight. High porosity nano-channel membranes, fabricated in the Cima lab, were also
able to retain MRSw functionalized to detect hCG. The apparent permeability for hCG through
these nano-channel membranes is about two orders of magnitude higher than for commercially
available polycarbonate membranes (10 nm pores). This increased Papp is most likely due to the
higher porosity (20% for nano-channel membranes vs. 0.05% for polycarbonate membranes) and
decreased thickness (50 nm for nano-channel membranes vs. 60 jtm for polycarbonate
membranes) of the nano-channel membranes.
3.2 Introduction
The MWCO membrane used in the sensing device should allow diffusion of the analyte
while restricting diffusion of MRSw, bond to the substrate material (see section 2.3.1) and be
biocompatible. Commercially available MWCO membranes were tested first for their ability to
restrict diffusion of MRSw. Analyte diffusion through two commercially available membranes,
polycarbonate and aluminum oxide that were able to restrict MRSw diffusion was then
quantified. High porosity membranes fabricated by Noel Elman, a post doc in the Cima lab, were
also characterized. These membranes were fabricated using a novel mass producible process that
combines laser interferometry lithography (LIL) to define nano-channels (pores), and micro-
machining techniques to produce free-standing amorphous silicon membranes (Figure 3-1).
Figure 3-1. High resolution SEM of a high porosity nano-channel membrane fabricated from a combination
of laser interferometry lithography and micro-machining tools. A 7x7 array of membranes, each 70x70 p.m
square, was fabricated with struts between them for increased mechanical support. This image is a a close-up
of one of the 70x70 p.m square membranes. Image provided courtesy of Noel Elman, PhD.
The chosen membrane material should also be biocompatible, since the MWCO
membranes will be used in in vivo sensing experiments. Polycarbonate is a common material in
medical devices and is considered biocompatible 45' 46 but adsorption of biomolecules to
nanoporous membranes due to implantation or incubation in serum containing media could
impair the device function over time47 . Adsorption of biological molecules onto the pore walls
would reduce the pore size and hinder or completely prevent analyte diffusion through the
membrane. Polycarbonate membranes were tested to determine the effects of biomolecule
adsorption on analyte diffusion.
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3.3 Materials and Methods
3.3.1 Ability to restrict MRSw
Several commercially available MWCO membranes were screened for ability to retain
MRSw: Aluminum oxide AnoporeTM (20 nm pores) and polycarbonate SPI-PoreTM (10, 30 and
50 nm pores) (SPI-Supplies, West Chester, PA), and polyethersulfone (100, 300 and 500 kDa
MWCO), (Millipore Corp, Bedford, MA). These membranes were tested with non-functionalized
MRSw which have an effective diameter around 40 nm by dynamic light scattering. MRSw that
have been functionalized on the surface with antibodies are usually slightly larger (80-90 nm).
The membranes were placed in a syringe-tip filter holder and a solution of CLIO-NH 2 (16 Rg
Fe/mL) was filtered through each membrane by applying steady, gentle pressure to the syringe
plunger. The amount of iron in the filtrate was quantified by proton relaxation time
measurements at 0.47 T and 400C (Bruker NMR Minispec, Billerica, MA).
This strict test for the ability to retain MRSw was used to identify membranes that would
be acceptable for use in any sensing experiment. Membranes that can retain the smallest, non-
functionalized MRSw when the solution is forced through the membrane will also be able to
retain larger functionalized MRSw when the only force for diffusion across the membrane is
passive diffusion. A second, less strict, test for the ability to retain MRSw was performed with
commercially available polycarbonate membranes (10, 30 and 50 nm pores) and with the high
porosity nano-channel membranes that were fabricated in the Cima lab. These membranes were
tested to see if they could prevent passive diffusion of functionalized MRSw.
Cup-shaped devices were made with polycarbonate membranes, filled with the
functionalized MRSw (80 nm diameter), and placed in PBS/BSA/PS for nearly two weeks. The
MRSw were functionalized with antibodies to detect human chorionic gonadotrophin (hCG), a
protein associated with testicular and ovarian cancer. The devices were kept at 370C and the T2
of the MRSw in the devices was periodically quantified by single-sided MR. An increase in T2,
caused by a decrease in the MRSw concentration, would indicate that the membrane was not able
to retain the MRSw inside the device. The sensitivity of the single-sided MR corresponds to a
detection limit of approximately 3% of the MRSw solution initially loaded in the devices.
The high porosity nano-channel membranes were placed in side-by-side glass diffusion
cells (PermeGear Inc, Bethlehem, PA) and a concentrated solution (40 pg Fe/mL) of
functionalized MRSw (80 nm diameter) was added to the donor side of the diffusion cells. The
MRSw were functionalized with hCG protein. The diffusion cells were kept at 370 C for one
week and then the solution on the receiver side was removed and the iron concentration in the
solution was quantified by proton relaxation time measurements on the single-sided MR (Profile
NMR MOUSE, ACT Center for Technology, Aachen, Germany). Dilutions of the concentrated
MRSw solution were used to generate a linear calibration curve relating l/T 1 to MRSw
concentration. The limit of detection using this NMR technique was 0.6 ug Fe/mL, which
corresponds to approximately 1.6% of the MRSw concentration that was initially loaded in the
diffusion cell.
3.3.2 Analyte diffusion
Side-by-side glass diffusion cells (PermeGear Inc, Bethlehem, PA) or 24-well plate
diffusion inserts (Nalge Nunc, Rochester, NY) were used to characterize analyte diffusion
through the MWCO membranes. Diffusion experiments were carried out at 370C in phosphate
buffered saline with 1 mg/mL bovine serum albumin (PBS-BSA) to minimize surface adsorption
of the analyte. Diffusion of 14C-dextran (Sigma, 40, 70 or 500 kDa), a model analyte, and 12 5I_
hCG (Perkin Elmer, 38 kDa) was studied. The separate components of the diffusion experiment
(membranes, diffusion cells, donor and receiver solutions) were incubated at 370C for at least 30
minutes before starting the diffusion experiment.
The 24-well plate diffusion inserts, shown in Figure 3-2, feature a 10-mm diameter
opening for diffusion and are preassembled with an AnoporeTM membrane (0.02 ptm pore size,
1011 pores/cm2). The receiver solution (600 uL of PBS-BSA) was added to each well of a 24-
well plate, then the diffusion inserts were placed in each well and the donor solution (500 uL of
analyte/PBS/BSA solution) was immediately added to each insert. One diffusion insert was
removed from the plate at each timepoint, the receiver solution was mixed, and 500 uL removed.
Receiver solutions were placed in a scintillation vial with 5 mL of scintillation fluid (ScintiSafe
Plus 50%, Fischer Chemicals, Fairlawn, NJ) and the amount of radioactivity was quantified by
scintillation (Packard Tri-Carb 2200CA, PerkinElmer, Waltham, MA). Raw data (disintegrations
per minute, DPM) were converted to nanocuries ( nCi) by using the conversion factor 2,200 dpm
= 1 nCi.
Figure 3-2. 24-well plate format for quantifying analyte diffusion through aluminum oxide membranes. A
close-up of the diffusion insert is shown in the bottom left corner. The insert held the radiolabeled analyte
solution and the solution in the well of the 24-well plate (receiver solution) was removed at each time point to
quantify the amount of radioactivity that had diffuse across the membrane. Each time point in a diffusion
experiment came from a different membrane.
The side-by-side diffusion cells, shown in Figure 3-3, have a 15 mm or 5 mm diameter
opening for diffusion and can be assembled with any MWCO membrane. The side-by-side
diffusion cell format was started by simultaneously adding the donor and receiver solutions
(approximately 4 mL each). Each compartment was continuously stirred throughout the
experiment. The receiver compartment was sampled at each time point by removing 100 uL of
solution and replacing it with fresh PBS/BSA. Receiver samples were placed in a scintillation
vial with 5 mL of scintillation fluid and the amount of radioactivity was quantified by
scintillation.
Figure 3-3. Side-by-side diffusion cell used to quantify analyte diffusion. The membrane is clamped between
the two glass chambers. A radiolabeled solution is added to one chamber and at each time point a small
volume of liquid is removed from the other chamber to quantify the amount of radioactive material that has
diffused across the membrane. In this experimental set-up, all the time points are taken using the same
membrane.
Diffusion of analyte into the receiver compartment can be described by Fick's first law:
dnrec = PappAc (Cd (t) - Crec (t)) (3-1)
dt
where n, is the amount of analyte in the receiver compartment, t is time, Papp is the apparent
permeability of the analyte (with dimensions of length/time), A, is the cross-sectional area for
diffusion, and Cd(t) and Crec(t) are the analyte concentrations in the donor and receiver
compartments at time t, respectively. The diffusion experiment was designed such that initially
Cre << Cd and Cd ; constant. Equation 3-1 simplifies with these conditions to:
= Prec AcCd, (3-2)
dt app cdJ
where Cd,i is the initial concentration of analyte in the donor compartment. Integrating equation
3-2 with the initial condition nec(O) = 0 results in:
nrec = PappAcCd,it . (3-3)
The apparent permeability can be calculated from the slope of a nrec vs time plot during the initial
diffusion (i.e Crec < 0.05Cd,i).
3.3.3 Adsorption of biomolecules
Ex vivo transport studies were performed to determine if adsorption of biomolecules
would significantly affect analyte diffusion into the device. Devices for ex vivo diffusion studies
had a ring-shaped polyethylene substrate (10 mm inner diameter). The devices were filled with a
PBS, 0.1% BSA, 1% penicillin-streptomycin solution and sealed on the back with a pressure
sensitive adhesive. The devices were soaked overnight in the same PBS/BSA/PS solution. Mice
were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10
mg/kg). Preemptive analgesics (buprenorphine, 0.1 mg/kg) were administered subcutaneously
before the first incision. The mice received a dorsal midline incision, and blunt dissection was
used to tunnel subcutaneously to the flank and create a pocket for the device. All devices were
placed in the pocket with the membrane facing the muscular layer and the incision was closed
with silk sutures. Mice were monitored daily for signs of distress and infection until the incision
healed, and were then monitored weekly. The devices were left in the mice for either one week
or one month and then explanted. The pressure sensitive adhesive on the back of the device was
removed after explantation and the device was placed in a side-by-side diffusion cell
(PermeGear) to quantify diffusion of 14C-dextran (40 kDa, Sigma-Aldrich) through the
membrane (see section 3.3.2). All work involving mice was performed according to the policies
of the Massachusetts Institute of Technology Committee on Animal Care. Mice were housed in
autoclaved cages and had access to autoclaved food and water ad libitum.
3.4 Results
3.4.1 Ability to restrict MRSw
Several of the MWCO membranes tested are able to restrict diffusion of the non-
functionalized MRSw (Table 3-1). Polycarbonate membranes (10 nm pores), aluminum oxide
membranes (20 nm pores), and polyethersulfone membranes (100 and 300 kDa MWCO) can
prevent the small non-functionalized MRSw from passing through even when the MRSw
solution is forced across the membrane. These membranes would be suitable for use in many
different in vitro and in vivo sensing applications.
Table 3-1. MRSw Retention Results
Retain Non-FunctionalizedMaterial Membrane Cut-Off Value
MRSw?
Polycarbonate 10 nm pores Yes
30 nm pores No
50 nm pores No
Aluminum Oxide 20 nm pores Yes
Polyethersulfone 100 kDa* Yes
300 kDa* Yes
500 kDa* No
An approximate conversion factor, assuming a globular protein conformation, is 100 kDa ~ 10 nm.
Two high porosity nano-channel membranes that were fabricated in the Cima lab were
able to retain functionalized MRSw (80 nm diameter) during a one week leak test. Figure 3-4
shows the 1/Ti values (measured using the single-sided MR) plotted against iron concentration,
with a relaxivity (RI) of 4.2x10 -4 jlg Fe/(mL*ms). After one week, the receiver solutions were
removed and the iron concentration for one of the membranes was found to be below the
detection limit (0.6 lig Fe/mL), meaning that more than 98.6% of the MRSw were retained by
the membrane. The concentration of the receiver solution for the other membrane was 0.7 [g
Fe/mL indicating that only 1.8% of the MRSw loaded in the donor cell was able to diffuse across
the membrane during one week. The high porosity nano-channel membranes are more brittle
than the commercially available polycarbonate membranes, and several nano-channel
membranes fractured during either analyte diffusion tests or MRSw leak tests. The design of the
nano-channel membranes can be changed to improve the mechanical stability. This would allow
the membranes to be used in device-based in vitro and in vivo sensing experiments.
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Figure 3-4. Relaxivity curve for calculating iron concentration in MRSw leak test with high porosity nano-
channel membranes. Error bars are calculated from the 95% confidence interval in the fit to determine T1.
Figure 3-5 shows MRSw leak test results for devices made with polycarbonate
membranes. Devices made with polycarbonate membranes with 50 nm pores showed a
significant increase in T2,eff after only two days, indicating that MRSw were able to diffuse out of
the reservoir by passing through the MWCO membrane. The T2,eff for the devices made with
polycarbonate membranes with 10 or 30 nm pores, however, were approximately constant for
nearly two weeks. This indicates that the MRSw were well contained within these devices,
according to the detection limit of the single-sided MR (able to detect a leak of 3% or more of
the MRSw solution in the device). This result was expected for the 10 nm pore membranes, since
they were able to retain non-functionalized MRSw when the solution was forced across the
membrane. The 30 nm pore membranes, however, allowed a significant portion of the non-
functionalized MRSw to cross the membrane when the solution was forced across the membrane.
These leak test results suggest that the 30 nm pore membranes would be an appropriate choice
for functionalized MRSw in short term (up to two week) sensing experiments. The benefit in
using 30 nm pore membranes in sensing experiments is that the percent porosity of the 30 nm
pore membranes (0.4%) is nearly ten times higher than for the 10 nm pore membranes (0.05%),
and therefore analyte diffusion should be faster in devices made with the 30 nm pore membranes.
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Figure 3-5. MRSw leak test for polycarbonate membranes with larger pores sizes and higher porosity. Cup-
shaped devices were in this leak test with pressure-sensitive adhesive for sealing the membrane to the device
substrate. The highest porosity membranes (50 nm pores, orange circles) showed immediate leaking ofMRSw. Error bars represent standard deviation (n = 4 in each group).
3.4.2 Analyte diffusion
We have demonstrated that high molecular weight analytes (38 kDa protein and up to 500
kDa dextran) are able to diffuse through polycarbonate membranes with 10 nm pores. Figure 3-6
is an example of data collected from side-by-side diffusion experiments with polycarbonate (10
nm pore) membranes. The slope of the trendline is directly equal to the apparent permeability,
with units of pm/min.
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Figure 3-6. Typical data for analyte diffusion through a polycarbonate (10 nm pore) membrane at 370C. Data
was collected using a side-by-side glass diffusion cell.
Table 3-2 shows the apparent permeability of several different compounds through the
polycarbonate, aluminum oxide, and high porosity nano-channel membranes. For the
polycarbonate and aluminum oxide membranes, Papp of 40 and 70 kDa 14C-dextran are similar,
but Papp of 12 5I-hCG (' 38 kDa) is significantly higher than 40 kDa dextran. This observation
suggests that for the range considered here, molecular weight is not the controlling factor in
diffusion. Previous studies have shown that analyte charge and conformation and membrane
characteristics (size, pore density, thickness, and charge) can also play a role in determining
app 48-50. The polycarbonate membranes were also tested with 500 kDa dextran, which has a Papp
approximately half that of 40 and 70 kDa dextran, indicating that molecular weight is beginning
to have an effect on diffusion at this size. The hydrodynamic radius of 40 and 70 kDa dextran is
similar (4.8 and 6.5 nm respectively) while 500 kDa dextran has a larger hydrodynamic radius
(16 nm)51. The hydrodynamic radii were calculated from viscosity data and represent the size of
a solid spherical particle that would be required to cause the same change in viscosity as
observed with the dextran molecules. The Papp is higher in the AnoporeTM and nano-channel
membranes than the SPI-PoreTM membranes, which is most likely due to different porosities
(31% for Anopore TM , 20% for nano-channel, and 0.05% for SPI-PoreTM). Although the
aluminum oxide membranes have a slightly higher percent porosity than the high porosity nano-
channel membranes, the Papp of 125I-hCG with the nano-channel membrane is more than twice as
high as with the aluminum oxide membrane. This is most likely due to the different thickness of
the two membranes: the pores in the aluminum oxide membrane are approximately 60 jm thick
while the nano-channels in the high porosity nano-channel membrane are only about 50 nm
thick. The shorter diffusion path in the high porosity nano-channel membranes results in a larger
Papp.
Table 3-2. Analyte Diffusion Results
Papp ( im/min)
Percent Pore 14C-Dextran 1251-hCG
Membrane Porosity Size 40 kDa 70 kDa 500 kDa (-38 kDa)(%) (nm)
AluminumAluminum 31 20 15.8±0.5 19.6±0.4 * 50+2
oxide
Polycarbonate 0.05 10 2.81±0.07 2.5±0.1 1.24±0.02 6.4±0.3
High porosity 20 60 * * * 170±70
nano-channel
* indicates that this analyte/membrane combination was not tested
The membrane permeability calculated from these diffusion experiments can be used
to predict analyte concentration inside a device at different time points. The in vitro sensing
experiments can be designed such that Vd >> Vrec, so the assumption that Cd & constant is still
a valid approximation. Equation 3-1 under this assumption simplifies to:
dCrec - Ac (Cd, - Crec (t)). (3-4)
dt Vrec
Integrating equation 3-4 with the initial condition Crec(O) = 0 results in:
Cre = Cd,i 1 (3-5)
From the Papp for 125I-hCG (6.4 pm/min for 10 nm pore polycarbonate membranes) and using
typical in vitro device dimensions (Ac = 0.02 cm 2 and Vree = 0.05 mL) the concentration inside
the reservoir should be approximately 95% of the donor bath concentration after approximately
20 hours. MR imaging in animal or clinical studies will be conducted on a daily or weekly basis,
so equilibrium diffusion time of approximately one day is an appropriate time frame for an in
vivo cancer sensor. The time to reach equilibrium for the same size device could be decreased to
approximately 7 hours if high porosity nano-channel membranes (Papp = 170 pm/min) were used
in the devices.
3.4.3 Adsorption of biomolecules
Ex vivo diffusion studies have shown that there is no noticeable decrease in analyte
transport after the membranes have been implanted for one week or one month. The apparent
permeability (Papp) for the analyte (dextran, 40 kDa) through the conditioned membranes (one
week: 3.0 +/- 0.5 p.m/min, n=3, one month: 2.9 +/- 0.2 p.m/min, n = 3) was approximately the
same as the Papp for fresh membranes (2.81+/- 0.07 Wm/min, n=3) 44 (p = 0.7 for one week, p =
0.4 for one month). Three of the one month devices showed a dramatic increase in the analyte
diffusion rate, indicating the presence of a defect in the membrane. These devices were excluded
from the Papp analysis, resulting in n = 3 for the Papp calculations. These results indicate that
adsorption of biomolecules onto the membrane pores does not have a significant effect on
analyte transport into the device for the implantation duration reported here. The higher
variability in the Papp of the conditioned membranes may be caused by manipulation of the
membranes during the device fabrication and implantation process.
3.5 Conclusion
Several commercially available membranes were identified that are able to both retain
MRSw and allow analyte diffusion. Analyte diffusion times are reasonable for an in vivo cancer
sensor device. The effect of biomolecule adsorption on polycarbonate membranes was tested in
an animal model. The diffusion of dextran (40 kDa) does not change significantly after the
membranes have been implanted for up to one month. High porosity nano-channel membranes,
made in the Cima group, were also tested. These membranes were able to retain MRSw
functionalized to detect hCG. The apparent permeability of hCG through the nano-channel
membranes is about two orders of magnitude higher than for commercially available
polycarbonate membranes (10 nm pores). Future studies should examine the effects of longer
implantation times and fibrous capsule formation on membrane biofouling and analyte transport.
Recent work with a silicon device gives promising evidence that a fibrous capsule may not
significantly hinder protein transport up to 6 months in beagle dogs52. Previous research has
shown that permeability of polycarbonate membranes in vivo can be enhanced by plasma surface
treatment45. We will explore this technique if in vivo transport kinetics vary significantly from in
vitro results after longer implantation times.
Chapter 4 Characterization of MRSw Aggregation
4.1 Summary
Several batches of MRSw functionalized to detect hCG were tested to determine the
stability of the MRSw, stability of the aggregates, and kinetics of aggregation. Some batches of
high valency MRSw were not suitable for device-based sensing, due to insolubility and
precipitation of aggregates. The batch of MRSw referred to as Cmix-3000 was found to form
stable aggregates in an appropriate time frame for device-based sensing. Cmix-3000 is a 50:50
mixture of C95-6 (3.5 Ab/CLIO) and C97-7 (3.7 Ab/CLIO). Many of the in vitro and in vivo
sensing experiments described in this thesis were performed with Cmix-3000.
4.2 Introduction
MRSw have previously demonstrated sensitive and specific aggregation in in vitro
agglutination assays2 1-26. These aggregation experiments, however, were carried out under
laboratory conditions that are difficult to reproduce in a device setting: the MRSw are stored at
40C before use, they are thoroughly mixed with the analyte solution, and the T2 of the
MRSw/analyte solution is quantified within ten minutes. A device-based sensing experiment
requires the MRSw to be kept inside the device at 370 C, the analyte must first diffuse across the
semi-permeable membrane and then throughout the MRSw solution, and the T2 measurement has
to be delayed to allow sufficient time for diffusion and aggregation. Previous work has shown
that MRSw behavior can vary significantly from batch to batch2 6 and that insolubility and
precipitation of aggregates is a common problem 26' 28 with higher valency MRSw. MRSw that
formed stable aggregates with hCG concentrations up to 6 ltg hCG/mL were preferred for the in
vitro and in vivo sensing experiments. The stability of the MRSw and the aggregates for specific
batches of MRSw functionalized to detect hCG was studied. The kinetics of aggregation when
the analyte is thoroughly mixed with the MRSw was also studied. The results of these
experiments were used to design in vitro and in vivo device-based sensing experiments.
4.3 Materials and Methods
4.3.1 Stability of MRSw
The ability of MRSw to aggregate depends on the stability of the antibodies attached to
the surface of the nanoparticle. The MRSw response to hCG was tested immediately after each
batch was functionalized. The two populations of MRSw (C95 and C97) were mixed in equal
ratios and diluted with PBS-BSA-PS to an MRSw concentration of 16 jig Fe/mL. Dilutions of
hCG (Sigma-Aldrich, St. Louis, MO), from 0.33 to 13.6 jg hCG/mL, were prepared in PBS-
BSA-PS. Equal volumes of the MRSw and hCG solutions were mixed together in an 8-well strip
and the T2,ff for each solution was quantified using the single-sided MR. The final MRSw
concentration was 8 jig Fe/mL and the final hCG concentrations ranged from 0.165 to 6.8 jig
hCG/mL. A control solution (8 jig Fe/mL, 0 jig hCG/mL) was also prepared and measured.
Stock solutions of the MRSw populations were stored at 40C. This test of the response of the
MRSw to hCG was repeated periodically to ensure that the MRSw were still able to aggregate in
the presence of hCG.
The ability of the MRSw to aggregate after being stored at 370C for one month was also
studied. Long term in vivo sensing experiments will depend on the MRSw being able to retain
their activity when stored in the device at 370C. The behavior of the MRSw in response to hCG
was tested as described above, and then some MRSw solution (50:50 mixture of the two
populations at 16 tg Fe/mL) was placed in an eppendorf tube and incubated at 370 C for one
month. The same test of the MRSw ability to aggregate in the presence of hCG was repeated at
the end of the one month incubation period.
4.3.2 Stability of aggregates and kinetics of aggregation
Successful in vivo sensing depends on the aggregates being able to form and then remain
stable enough to cause a decrease in T2 after being incubated at 370 C for up to four days. The
kinetics of aggregation and stability of aggregates was tested using the same hCG/MRSw
solutions described above (Section 4.3.1). The hCG/MRSw solutions were stored in a capped 8-
well strip at 370 C and the T2,eff of the solutions was measured periodically using single-sided MR.
The solutions were allowed to cool to room temperature before each reading.
4.4 Results
4.4.1 Stability of MRSw
The combination of MRSw batches that proved to be the most stable when stored at 40C
were the sixth batch of C95 particles (3.5 Ab/CLIO) and the seventh batch of C97 particles (3.7
Ab/CLIO). These batches were prepared at the end of September 2007 and this specific
combination of MRSw populations is referred to as Cmix-3000. Figure 4-1 (orange bars) shows
the response of Cmix-3000 to hCG solutions of 0, 0.167, 0.34, 0.68 and 1.67 tg hCG/mL just
days after they had been functionalized. The green bars in Figure 4-1 show the response of the
Cmix-3000 MRSw after the stock solutions had been stored at 40C for seven months. One thing
to note from Figure 4-1 is that the T2,eff value for each solution increased slightly after seven
months in storage. This is most likely due to precipitation of some particles in the stock
solutions, resulting in an actual iron concentration that is slightly lower than expected (a decrease
in iron concentration corresponds to an increase in T2,eff). The second thing to note from Figure
4-1 is that after 7 months of storage at 40 C the MRSw are still able to aggregate and the decrease
in T2,eff when the MRSw are mixed with hCG is just as pronounced as it was immediately after
the MRSw were functionalized. Another batch of MRSw that were tested (C95-4 and C97-4) had
a decrease in T2,eff that was much smaller in magnitude when comparing MRSw that had been
stored at 40C for just over four months to recently functionalized MRSw.
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Figure 4-1. Ability of MRSw (Cmix-3000) to aggregate in the presence of hCG. MRSw and hCG solutions
were mixed together and placed in an 8-well strip. T2,eff values shown are from approximately 10 minutes
after the two solutions were mixed. Orange bars represent the behavior of Cmix-3000 a few days after it wasfunctionalized to detect hCG. Green bars represent Cmix-3000 after stock solutions are stored at 40C for 7
months. Error bars represent 95% confidence intervals in the fit to determine T2,eff.
The ability of Cmix-3000 to aggregate in the presence of hCG after being stored at 370C
for one month was also studied. Cmix-3000 was stored at 16 tg Fe/mL. Figure 4-2 shows the
behavior of Cmix-3000 MRSw a few days after they were functionalized to detect hCG (orange
bars) and again after the stock solutions had been stored at 37C for one month (green bars). The
T2,ff of all solutions increased after one month at 370C, again most likely caused by some MRSw
precipitating out of solution. The magnitude of the shift up in T2,eff is larger than was observed
when the MRSw were stored at 40C for one month. A more significant change is that the
magnitude of the T2,eff decrease with addition of hCG is dramatically reduced after incubation at
370C for one month. Concentrations that showed a significant decrease in T2,eff initially are now
very similar to the T2,eff of the control solution.
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Figure 4-2. Ability of MRSw (Cmix-3000) to aggregate in the presence of hCG. MRSw and hCG solutions
were mixed together and placed in an 8-well strip. T2,eff values shown are from approximately 10 minutes
after the two solutions were mixed. Orange bars represent the behavior of Cmix-3000 after it had been stored
at 40C for seven months. Green bars represent the behavior of Cmix-3000 after the stock solutions were
stored at 37C for one month. Error bars represent 95% confidence intervals in the fit to determine T2,eff.
4.4.2 Stability of aggregates
Stable aggregates are required for successful in vivo sensing. Figure 4-3 shows the
behavior of low valency MRSw over nearly ten days. The MRSw solution is a 50:50 mixture of
C95-4 (2.0 Ab/CLIO) and C97-4 (2.3 Ab/CLIO) at a final concentration of 8 jig Fe/mL. When
the MRSw are mixed with hCG at a final concentration of 0.68 [g hCG/mL (ratio of one hCG
molecule per MRSw particle) (filled pink circles) stable aggregates are formed, as seen by a
decrease in T2,eff that is stable over the course of the experiment. The control solution (MRSw
with no hCG present, open pink circles) also remains constant over the course of the experiment.
These MRSw were used in initial in vitro sensing experiments.
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Figure 4-3. Aggregate stability with low valency MRSw. A 50:50 mixture of C95-4 (2.0 Ab/CLIO) and C97-4(2.3 Ab/CLIO) was mixed with an equal volume of PBS or hCG and T2,ff was periodically measured using
single-sided MR. Final MRSw concentration was 8 g±g Fe/mL for the control and sample solutions. Final hCG
concentrations for the control and sample solutions were 0 and 0.68 ptg hCG/mL, respectively. Solutions werekept at 37 0C between time points. Error bars represent 95% confidence interval in the fit to determine T2,eff.
Figure 4-4 shows the behavior of high valency MRSw over nearly ten days. This MRSw
solution is a 50:50 mixture of C95-2 (4.1 Ab/CLIO) and C97-2 (4.5 Ab/CLIO) at a final
concentration of 8 [tg Fe/mL. There is an immediate decrease in T2,eff, caused by aggregation of
the MRSw, when the MRSw are mixed with hCG at a concentration of 0.68 pg hCG/mL (ratio of
one hCG molecule per MRSw particle, filled green squares). The T2,ff is not stable, however, and
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just 30 minutes after mixing the two solutions together the T2,ff of the hCG solution is higher
than the control solution (open squares). The T2,ff of the control solution (no hCG) remains
stable over the course of the experiment. Particle size data for these high valency MRSw confirm
that the aggregates quickly grow to about one micron in size26. Precipitates can be seen on the
bottom of the cuvette if the solutions are left standing overnight. These MRSw were not used in
device-based sensing experiments since instability and precipitation of aggregates was observed
even at the relatively low hCG concentration of 0.68 ptg hCG/mL.
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Figure 4-4. Aggregate instability with high valency MRSw. A 50:50 mixture of C95-2 (4.1 Ab/CLIO) and
C97-2 (4.5 Ab/CLIO) was mixed with an equal volume of PBS or hCG and T2,ff was periodically measured
using single-sided MR. Final MRSw concentration was 8 lg Fe/mL for the control and sample solutions.
Final hCG concentrations for the control and sample solutions were 0 and 0.68 lg hCG/mL, respectively.
Solutions were kept at 37C between time points. Error bars represent 95% confidence interval in the fit to
determine T2,eff.
Kinetics of aggregation when MRSw and hCG are thoroughly mixed together was
studied for Cmix-3000. Figure 4-5 shows that the lower hCG concentration solutions (blue
diamonds and pink squares) cause a small but steady decrease in T2,eff over three days at 370C.
The control solution (no hCG present, open purple circles) also exhibits a stable T2,ff. The higher
hCG concentrations, however, (orange triangles and brown circles) show an immediate drop in
T2,ff and then a continued decrease in T2,eff for nearly 24 hours at the highest hCG concentration
(6.8 pg hCG/mL). This data suggests that smaller aggregates form rather quickly at low and high
hCG concentrations, but at high hCG concentrations the aggregates continue to grow for up to 24
hours after mixing. These MRSw were used for both in vitro and in vivo sensing experiments
because they form stable aggregates at the range of hCG concentrations studied. Even these
MRSw, however, would be expected to show instability of aggregates at either higher hCG
concentrations or longer times.
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Figure 4-5. Kinetics of aggregation when analyte and MRSw are thoroughly mixed together. The MRSw
batch used in these experiments is Cmix-3000. Solutions were stored in an 8-well strip at 370 C between time
points. Error bars represent 95% confidence limits in the fit to determine T2,eff.
Figure 4-3, Figure 4-4 and Figure 4-5 show that the time required for larger aggregates to
form depends both on MRSw valency and hCG concentration. This delayed aggregation could
have a significant impact on device-based sensing. The concentration of hCG inside the device
will be roughly equal to the hCG concentration outside the device after one day in the analyte
bath solution (see Section 3.4.2) for the in vitro and in vivo sensing devices considered in this
thesis. The delay in aggregation should not significantly affect the behavior of the device since
both events (diffusion and aggregation) are occurring on the same time scale for the MRSw and
hCG concentration ranges shown in Figure 4-5. The smaller aggregates will form quickly and the
larger aggregates will have time to form as the hCG continues diffusing into the reservoir.
Higher hCG concentrations, however, could take longer than 24 hours to reach a stable T2,ff.
This would result in the T2,eff continuing to decrease past the time when the hCG concentration
inside the reservoir is calculated to be at equilibrium.
4.5 Conclusion
The batch of MRSw referred to as Cmix-3000 was found to retain activity after being
stored at 40C for seven months. Much of the activity of Cmix-3000 was lost, however, after
incubation at 370 C for one month. The MRSw were still able to aggregate, but the operating
range of hCG concentrations was significantly smaller and the decrease in T2,eff was less
pronounced. Stability of aggregates was found to be a function of both MRSw valency and hCG
concentration, as expected. Cmix-3000 was found to form stable aggregates for a range of hCG
concentrations relevant to in vivo experiments and this batch of MRSw was used for many
device-based sensing experiments. The kinetics of aggregation for Cmix-3000 may take longer
than diffusion of hCG into the device for higher hCG concentrations. This would result in a
prolonged decrease in T2,eff in device-based sensing experiments.
The ability to perform long term in vitro and in vivo sensing experiments depends on
MRSw that retain activity when stored at 370C and produce stable aggregates. Previous work has
demonstrated that stabilization of MRSw aggregates can be achieved by trapping them in a
matrix that prevents the aggregates from precipitating out of solution53. Stability of the MRSw at
370C may be able to be improved by adding PEG as a linker when attaching the antibodies to the
surface of the MRSw 54 or by adding hydrophobic mutations or disulfide bonds to the antibody55
Chapter 5 In Vitro Device-Based Sensing
5.1 Summary
These in vitro sensing experiments are the first step in developing an implantable
device for sensing soluble cancer related analytes. These devices have the potential for real
time and noninvasive repeat monitoring of local conditions in vivo and the format lends itself
to a multiplexed device to allow sensing of multiple analytes. We have demonstrated that the
analyte (hCG) is able to diffuse across the semi-permeable membrane and cause aggregation
of the MRSw. These MRSw aggregates are stable enough in the sensing device to show a T2
decrease after being incubated in analyte solutions at 370C for up to three weeks. The
stability of the aggregates depends on the concentration of analyte being detected and the
type of membrane used in the device. Higher porosity membranes lead to less stable
aggregates, suggesting that the increase in T2 at longer times is caused by either the prozone
effect or the aggregates growing so large that they precipitate out of solution.
5.2 Introduction
There are several unique advantages to the sensing device described here. First, MR
imaging can be used to read the device even if it is implanted deep within the body. Second, the
fixed reservoir volume maintains a constant iron concentration. Changes in T2 can be directly
attributed to changes in aggregate size, which allows for quantitative analysis of analyte
concentrations. The optimum MRSw concentration for a sensing experiment depends on both the
concentration of analyte being detected and the sensitivity of the NMR technique used to
quantify T226. These in vitro sensing experiments are an important first step in developing an
implantable sensor for detecting soluble cancer biomarkers in vivo.
5.3 Materials and Methods
5.3.1 MRI detection
PDMS devices were fabricated as described in section 2.3.1 and filled with a 50:50
mixture of the two MRSw populations functionalized to detect hCG (C95 and C97) with a final
MRSw concentration of 2, 6, 10 or 16 tg Fe/mL. Solutions of known hCG-b concentrations
(Scripps Laboratories, 28 kDa) were made in PBS-BSA. The devices were placed in the hCG-b
solutions (0.5, 1.5, 3.0 or 5.0 gg hCG-b/mL) at 370C. These analyte concentrations were
previously shown to be in the appropriate range for detection with the MRSw functionalized to
detect hCG 26. Control devices were placed in PBS-BSA. There were at least two devices in each
group.
The first sensing experiment with MRI detection was conducted using a 24-well plate to
hold the devices and analyte bath solutions. The devices were removed at each imaging time
point, blotted on a tissue to remove any drops of analyte solution, and placed together on a piece
of plastic for MR imaging. Subsequent sensing experiments were conducted using a custom-
machined tool that allowed the devices to remain in their respective analyte bath solutions during
MR imaging.
Equilibrium hCG-b concentrations were approximately equal to the initial bath
concentration because the bath volume (700 uL) was much larger than the reservoir volumes (12
uL each). Two separate MR imaging sessions (Bruker, 4.7T), approximately 24 hours apart, were
used to monitor the change in T2 of the MRSw solutions in the PDMS devices. Total MR
imaging time was approximately 1 hour at each time point. The imaging protocol was a T2 -
weighted multi-slice, multi-echo scan (TR 6000 ms, variable TE 15 - 1500 ms, 4x4 cm field of
view, 128x128 imaging matrix, spectral width of 50,000 Hz, 3 slices, 0.7 mm slice thickness,
number of excitations = 2). MRI data was analyzed using Matlab (Matlab 7.1, The MathWorks,
Natick, MA) to produce a T2 map. Table 5-1 summarizes the experimental plan for these in vitro
sensing experiments.
Table 5-1. Experimental Plan for In Vitro Sensing with MRI Detection.
MRSw Concentration Analyte Bath Concentrations Elapsed Time Before Imaging
(pg Fe/mL) (pg hCG-b/mL) (hrs)
2 0, 0.5, 1.5, 3 3, 27
10 0, 3, 5 1, 5, 25, 2910 1,25
16 0, 3, 5 1, 5, 25, 2910 1, 25
5.3.2 Single-sided MR detection
MRI is the gold standard for T2 measurements in vivo, but it is time and cost-intensive.
Single-sided MR easily allows for multiple time points and devices and is preferred for in vitro
device-based sensing experiments. A device can be read on the single-sided MR, for both T and
T2, in about one minute. Single-sided MR analysis allows the kinetics of aggregation to be
studied in device-based sensing experiments.
5.3.2.1 Optimizing device design
Washer shaped devices were fabricated as described in Section 2.3.2 using two methods
to attach the MWCO membrane to the substrate: a silicone adhesive and a double-sided pressure
sensitive adhesive. The devices were filled with MRSw functionalized to detect hCG and placed
in a bath of PBS-BSA-PS at room temperature. Single-sided MR was used to quantify the T2,eff
immediately after fabrication and again almost one day later. Devices were then placed in
analyte baths of 0.7 jig hCG/mL and kept at 370C. The devices were removed from the analyte
baths periodically to quantify T2,eff Of the MRSw in the reservoirs.
5.3.2.2 Lower analyte concentrations
Cup devices were fabricated as described in Section 2.3.2. The reservoirs were filled with
MRSw designed to aggregate in the presence of hCG (8 glg Fe/mL). Single-sided MR was used
to quantify the T2,ff of the MRSw in each device immediately after fabrication and again after 12
- 24 hours to confirm that the devices were not leaking (an increase in T2,eff is correlated to a
decrease in iron concentration). Sample devices were placed in analyte baths (0.1, 0.2, 0.3 and
0.4 gg hCG/mL) and incubated at 370C (n = 4, 2, 4 and 4 respectively). Control devices (n = 4)
were placed in PBS-BSA-PS. Devices were periodically removed from the analyte bath and T2,eff
measurements were taken on the single-sided MR after the devices cooled to room temperature.
5.3.2.3 Higher porosity membranes
Cup devices were fabricated as described in Sections 2.3.2 with 10 nm or 30 nm pore
polycarbonate membranes. The 30 nm pore membranes have a percent porosity that is
approximately ten times higher than the 10 nm pore membranes. Devices with the 30 nm pore
membranes are expected to show a faster decrease in T2,eff compared to 10 nm pore membrane
devices. The reservoirs were filled with MRSw designed to aggregate in the presence of hCG (8
gg Fe/mL). Single-sided MR was used to quantify the T2,ff of the MRSw in each device
immediately after fabrication and again after 12 - 24 hours to confirm that the devices were not
leaking. Sample devices (n = 4 for 10 nm pore membranes, n = 5 for 30 nm pore membranes)
were placed in analyte baths of 1 jig hCG/mL and control devices (n = 4 for each pore size) were
placed in PBS-BSA-PS solutions. Devices were periodically removed from the analyte bath for
T2,ff measurements on the single-sided MR after the devices cooled to room temperature. Time
points were taken for two weeks.
5.3.2.4 MRSw incubation in devices at 370C
Devices described in Section 5.3.2.3 were also used to test the stability of MRSw when
stored in devices at 370 C for two weeks. Two of the control devices (for each pore size) were
moved into an hCG analyte bath (1 p~g hCG/mL) after taking time points as described in section
5.3.2.3 for two weeks. The behavior of these devices was compared to the sample devices that
had been in hCG baths for the previous two weeks and the control devices that remained in the
PBS-BSA-PS solutions. This experiment was designed to mimic an in vivo sensing experiment
where the analyte is not present at the time of device implantation (for example, if the device was
used to detect metastasis).
5.4 Results and Discussion
5.4.1 MRI detection
These in vitro sensing experiments have demonstrated the ability to detect hCG-b within
silicone devices. A typical image from the first in vitro sensing experiment with MRI detection is
shown in Figure 5-1. Each light square in the image is a device reservoir. The average intensity
of each reservoir at each TE was calculated using Matlab and used to produce relaxation curves
similar to those shown in Figure 5-2.
Figure 5-1. Representative MRI image from in vitro sensing with PDMS devices. Each light square represents
a reservoir filled with MRSw. The average intensity of each reservoir at each echo time was calculated from
this type of image. The decay in intensity for each reservoir as a function of echo time was used to calculate
the T2 of the MRSw solution (Equation 5-1).
The T2 relaxation time can be calculated by fitting the MRI data to an equation of the form:
TE
AvgI = Ae T2 +B. (5-1)
Where AvgI is the average intensity, TE is the echo time, A is the amplitude and B is the offset.
The curves in Figure 5-2 are for the control devices (6, 10 and 16 pg Fe/mL) and for pure PBS.
The T2 of the control devices increases as the iron concentration decreases, agreeing with
previously reported experiments 43
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Figure 5-2. MRI decay curves used to calculate T2 for solutions of MRSw only (no analyte present). An
increase in MRSw concentration corresponds to a decrease in T2.
Several of the devices in the first sensing experiment showed a significant increase in T2
at the second time point. Figure 5-3 shows the mean T2 of devices filled with 10 pg Fe/mL at
each time point for this first sensing experiment (error bars represent st. dev.). Previous testing of
the polycarbonate membranes used in these devices showed that the MRSw are not able to pass
through the membrane (Section 3.4.1). The increase in T2, therefore, is due to either failure of the
membrane/substrate seal or leaking of the MRSw from the back of the device, which was sealed
with pressure sensitive adhesive after filling the reservoir with MRSw. None of the devices in
this experiment showed a decrease in T2, perhaps because any decreases in T2 due to aggregation
were masked by increases in T2 due to MRSw leakage.
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Figure 5-3. Mean T2 for PDMS devices filled with MRSw at 10 gg Fe/mL and placed in hCG baths of 0, 3, 5or 10 jtg hCG/mL. Several devices showed a significant increase in T2 at the second time point (greencolumns), indicating leakage of the MRSw.
The PDMS substrate is very flexible and the seal with the membrane was most likely
damaged when the devices were transferred from the analyte baths for imaging. Some reservoirs
also developed air bubbles while the devices were being imaged, since they were kept out of the
analyte baths for approximately one hour at each imaging time point. These difficulties were
solved by designing a tool that allowed the devices to be imaged while remaining in their analyte
baths. Figure 5-4 shows a typical MRI image using this tool. Each light square is a device
reservoir and the light regions around the devices are the analyte bath solutions. This tool
allowed the devices to be left in the analyte bath solutions once filled, which decreased the
occurrence of MRSw leaks and allowed detection of the decrease in T2 due to aggregation.
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Figure 5-4. Typical MR image from sensing experiments where devices remained in analyte bath duringimaging. Each light square represents a reservoir filled with MRSw in the PDMS device. Light regions
around the PDMS devices are from the baths of analyte solution.
Figure 5-5 shows T2 data for the devices filled with 16 ptg Fe/mL CLIO solutions. The
top figure shows the average T2 values and the bottom figure shows the average percent change
in T2 compared to the control devices:
% change in T = T2 -Avg T trl *100 (5-2)Avg_ T2ctrl 0
where Avg_ Tctrl is the average T2 of the control devices at the same time point. The error bars
represent either the standard deviation for the group or the error associated with the calculated T2
values (95% confidence limit). Errors were calculated using both methods and the higher value is
reported. The T2 of the control devices remained constant over the course of the experiment,
suggesting that the nanoparticles were well contained in the device.
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Figure 5-5. In vitro sensing results with PDMS devices filled with MRSw at 16 jig Fe/mL. Devices were placed
in analyte baths of 0, 3 or 5 jig hCG/mL. Error bars represent either standard deviation (n=2 for each group)
or 95% confidence limit in the fit to determine T2 (the larger error is reported).
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Figure 5-5 shows that at the first imaging time point (5 hours) only the devices placed in
5 Ig hCG-b/mL solutions showed a significant drop in T2. The hCG-b concentration inside the
device at each time point can be predicted using Equation 3-5, assuming that Papp for hCG-b is
the same as for 125I-hCG. The concentration inside the reservoir, for example, should be
approximately 50% of the analyte bath concentration 5 hours after being placed in the analyte
solution. The second time point (about 24 hours after the first time point) is sufficient time for
the concentration inside the reservoir to reach 98% of the initial analyte solution concentration.
The devices in both analyte bath solutions (3 and 5 mg hCG-b/mL) showed a significant
decrease in T2 by the second time point, approximately 29 hours after the devices were placed in
the analyte baths.
Devices with MRSw concentrations of 10 jlg Fe/mL were also tested in analyte solutions
(3 and 5 lg hCG-b/mL). Percent change in T2 for these devices is summarized in Table 5-2 and
compared with the behavior of the devices filled with 16 lg Fe/mL MRSw. The 16 jg Fe/mL
devices in the 3 jg hCG-b/mL analyte solution were the only ones that did not show T2 decreases
at the firs time point. All devices showed T2 shortening at 29 hours. Previous studies have shown
that the magnitude of T2 shortening depends on the ratio of analyte molecules to MRSw
molecules26 . Similar trends were seen with the sensing devices at the 5 hour time point. The 10
jLg Fe/mL devices show a larger percent change in T2 at 5 hours than the 16 ig Fe/mL devices.
Table 5-2. Results for In Vitro Sensing of hCG-b with MRI detection.
% Change in T2 Compared to Control Devices
3 Lg hCG-b/mL 5 g hCG-b/mL
[CLIO] Analyte Solution Analyte Solution
5 hours 29 hours 5 hours 29 hours
10 g Fe/mL -8 ± 4 -27 + 3 -16 2 -25 + 3
16 ig Fe/mL -4 ± 5 -27 ± 5 -9 ± 3 -26 ± 7
Detection of lower concentrations of hCG-b was attempted using devices with lower
MRSw concentrations. Devices were filled with either 2 or 6 ug Fe/mL and placed in hCG baths
of 0.5, 1.5 and 3 pg hCG-b/mL. Figure 5-6 shows T2 data for the devices filled with 6 gg Fe/mL
MRSw solutions. The top figure shows the average T2 values and the bottom figure shows the
average percent change in T2 compared to the control devices. The error bars represent either the
standard deviation for the group or the error associated with the calculated T2 values (95%
confidence limit). Errors were calculated using both methods and the higher value is reported.
The T2 of the control devices, again, remained constant over the course of the experiment,
suggesting that the nanoparticles were well contained in the device. Figure 5-6 shows that at
three hours devices in the 3 ptg hCG-P/mL analyte bath showed T2 shortening. Devices in all
three analyte baths showed T2 shortening in a concentration dependent manner at the 27 hour
time point.
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Figure 5-6. In vitro sensing results with PDMS devices filled with MRSw at 6 gg Fe/mL. Devices were placed
in analyte baths of 0, 0.5, 1.5 or 3 tg hCG/mL. Error bars represent either standard deviation (n=2 for each
group) or 95% confidence limit in the fit to determine T2 (the larger error is reported).
Table 5-3 summarizes the T2 results for the 2 and 6 ptg Fe/mL devices. Only the
devices in the 3 tg hCG-b/mL bath showed a significant decrease in T2 at the first time point,
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but all devices showed a significant decrease in T2 at the second time point. The ability to
detect aggregation in devices placed in analyte baths as low as 0.5 pg hCG-b/mL is
significant for in vivo sensing experiments. Section 6.4.1 shows that mice with tumors that
secrete hCG-b have plasma concentrations around 0.5 jig hCG-b/mL approximately 7-10
days after tumor induction.
Table 5-3. In Vitro Sensing Results for Devices with MRSw concentrations of 2 or 6 gg Fe/mL.
% Change in T2 Compared to Control Devices
0.5 jtg hCG-b/mL 1.5 ig hCG-b/mL 3 ptg hCG-b/mL
[CLIO] Analyte Solution Analyte Solution Analyte Solution
3 hours 27 hours 3 hours 27 hours 3 hours 27 hours
2 tg Fe/mL 3 ± 4 -13 ± 2 -4 + 3 -13 ± 3 -6 + 1 -10 3
6 jtg Fe/mL 0 + 1 -9 +2 -1 + 2 -18 + 2 -4 ± 2 -22 + 2
These experiments demonstrated that the MRSw aggregates are stable enough in the
sensing device to show a decrease in T2 after incubation in analyte solutions at 370C for
approximately 29 hours. Future in vitro studies looked at the stability of MRSw aggregates at
longer time points. The frequency of time points was also increased to study the kinetics of
device operation.
5.4.2 Single-sided MR detection. optimizing device design
The behavior of washer devices with either silicone adhesive or double-sided pressure
sensitive adhesive used to attach the membrane to the device substrate was studied in an in vitro
sensing experiment. Figure 5-7 shows the percent change in T2,ff, which was calculated using:
(T2,eff - Avg2,eff)
% change in T2,eff = Avg2,eff *100 (5-3)
AvgT2,eff
where Avg2,eff is the average T2,eff readings for the device before it was placed in the hCG
solution. Devices made with double-sided pressure sensitive adhesive showed a significant
decrease in T2,eff after being in the hCG solutions for just half a day. Devices made using a
silicone adhesive, however, did not start to show a significant decrease in T2,eff until two days
after being placed in the hCG solutions. It is possible that the silicone adhesive spread onto the
polycarbonate membrane covering the reservoir, reducing the cross-sectional area for diffusion
of the hCG into the reservoir. Uncured adhesive could also leach into the reservoir and interfere
with the MRSw or hCG, causing a delay in the T2,eff decrease. This delay in T2,eff decrease was
avoided in future experiments by using double-sided pressure sensitive adhesive to seal the
membrane to the device substrate.
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Figure 5-7. Comparison of two methods for adhering membranes to device substrate: silicone adhesive (blue
diamonds) or double-sided pressure sensitive adhesive (pink squares). Devices were placed in analyte baths of
0.7 jig hCG/mL. The percent change in T2,eff of the devices, compared to control devices placed in PBS
solutions, is reported on the y-axis. Error bars represent standard deviation (n = 2 for each group).
5.4.3 Single-sided MR detection. lower analyte concentrations
Device-based detection of lower analyte concentrations was demonstrated. Figure 5-8
shows the T2,eff for each group of devices as a function of time. The control devices (open
diamonds) maintained a constant T2, eff over the ten day period indicating that the MRSw did not
leak from the reservoirs. The decrease in T2,eff at each time point was larger for higher analyte
concentrations for the first four days. The T2,ff of the devices in the highest concentration analyte
bath began to increase slowly after this time point, indicating instability of the aggregates or
leaking of MRSw. Devices in the lowest analyte concentration (pink squares) showed a
significant decrease in T2,eff by day four. The difference between the sample and control devices
was even more pronounced by day nine. These results suggest that device-based sensing of low
concentrations of analyte is possible if enough time is allowed for the analyte to diffuse into the
reservoir and cause aggregation.
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Figure 5-8. In vitro device based sensing of low hCG concentrations using cup-shaped devices with
polycarbonate (10 nm pore) membranes. T2,eff for control devices, placed in PBS solutions, (open diamonds)
remained constant while devices placed in hCG solutions (filled symbols) showed a decrease in T2,eff. Error
bars represent standard deviation.
Figure 5-9 compares the maximum percent change in T2,ff (compared to control solutions
or devices) when the hCG and MRSw are thoroughly mixed together (Figure 4-5) and when the
MRSw are contained within a device (Figure 5-8 and Figure 5-10). Figure 5-9 shows that for
analyte concentrations between 0.1 to 1 [g hCG/mL, a larger decrease in T2,eff will be observed
with device-based sensing. This suggests that the detection limit of the MRSw may be lower
when they are used within a device. The high binding affinity of the antibodies favors
irreversible MRSw. The signal measured is, thus, an integral of total exposure to the analyte over
time and as such could be significantly more sensitive. Further studies at lower hCG
concentrations need to be performed to verify this preliminary observation.
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Figure 5-9. Comparison of maximum percent changes in T2,eff for direct mixing of hCG and MRSw and
device-based sensing of hCG. Error bars represent 95% confidence interval in the fit to determine T2,ff for
the direct mixing of hCG and MRSw data. Error bars represent standard deviation for the device-based
sensing data (n = 2 or 4).
5.4.4 Single-sided MR detection: higher porosity membranes
Figure 5-10 shows that the T2,eff of the control devices remained constant over the course
of the experiment, suggesting that the nanoparticles were well contained in the devices by both
the 10 and the 30 nm pore membranes. Devices placed in hCG solutions, however, showed a
significant decrease in T2,eff. This suggests that hCG was able to diffuse across the MWCO
membrane and cause aggregation of the MRSw. Devices with 10 nm pore membranes showed a
decrease in T2,ff for approximately four days after being placed in the hCG solution. Devices
with 30 nm pore membranes showed a faster and slightly larger decrease in T2,eff suggesting that
the diffusion of hCG into the device is faster with the 30 nm pore membranes. The 30 nm pore
- direct mixing of hCG and MRSw
I
I I
A
membranes have a percent porosity that is nearly ten times higher than the 10 nm membranes
which most likely explains the faster diffusion with the 30 nm pore membranes.
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Figure 5-10. In vitro device based sensing with single-sided MR detection. Cup-shaped devices were made
with either 10 nm (blue squares) or 30 nm (pink circles) pore polycarbonate membranes. Devices placed in
hCG solutions (filled symbols) showed a decrease in T2,eff while control devices placed in PBS (open sympols)
maintained a constant T2,eff . Error bars represent standard deviation.
Figure 5-10 shows that the devices placed in analyte baths of 1 p~g hCG/mL begin to
show a gradual increase in T2,eff around day two for the devices with 30 nm pore membranes and
day eight or nine for the devices with 10 nm pore membranes. The devices with 30 nm pore
membranes initially show a sharper decrease in T2,eff but by day five there is no significant
difference in T2,eff for the two types of devices. By day 12 the devices with 30 nm pore
membranes have a slightly higher T2,ff than the 10 nm pore membrane devices. It is unlikely that
this increase in T2,eff is caused by MRSw leaking out of the reservoir, since none of the eight
control devices exhibit this behavior. The increase in T2,eff could be caused by the prozone effect,
instability of the aggregates (i.e. "crashing out"), instability of the antibodies attached to the
surface of the MRSw, or leaking of MRSw. The standard deviation for each group of devices
placed in hCG solutions is small, suggesting that the increase in T2,ff is not due to leaking of
MRSw, since it is unlikely that all the sample devices would leak MRSw at the same rate while
all of the control devices were able to contain the MRSw. The kinetics of aggregation for devices
with 10 nm pore membranes is slower but seems to be more stable over a two week time period.
Devices with 30 nm pore membranes would only be preferred for very short term sensing
experiments, on the order or one or two days, due to the instability of the aggregates at longer
time points for the combination of analyte and MRSw concentrations used in this experiment.
5.4.5 Single-sided MR detection: MRSw incubation in devices at 3 70C
The in vitro sensing experiment described in Section 5.4.4 was continued for an
additional two weeks. This experiment was designed to mimic an in vivo sensing experiment
where the analyte is not present at the time of device implantation (for example, if the device was
used to detect metastasis). Two control devices of each type of device (10 nm and 30 nm pore
membranes) were switched into 1 tg hCG/mL solutions at day 13. Figure 5-11 shows data for
the entire experiment. One of the control devices with a 10 nm pore membrane began to leak
(increase in T2,eff) around day 14, so this data was excluded from Figure 5-11. The dashed lines
represent devices that began in control solutions and were switched to hCG solutions at day 13.
A decrease in T2,eff was detected in all four of these devices, indicating the that MRSw stored in
the devices for nearly two weeks at 370C were still able to aggregate in the presence of hCG. The
lowest T2,eff for these four devices was slightly higher than the lowest T2,eff of devices that were
placed directly in hCG solutions. The subsequent increase in T2,eff was also slightly more
dramatic for the four devices that were placed in PBS solutions for nearly two weeks. These
results support choosing 10 nm pore membranes for sensing experiments that will last longer
than a few days, since for the analyte and MRSw concentrations studied here the T2,eff is slightly
more stable in the 10 nm pore membrane devices.
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Figure 5-11. Device-based sensing after incubation in PBS for two weeks at 370C. The experiment shown in
Figure 5-10 is continued in this figure. Two of the devices that had previously been incubated in PBS
solutions were switched to 1 g.g hCG/mL solutions at day 14 (dashed lines). Error bars represent standard
deviation.
5.5 Conclusion
Multiple in vitro sensing experiments have demonstrated the ability to detect the presence
of hCG using MRSw that are contained within a reservoir by a semi-permeable membrane.
Aggregation of the MRSw within the device was detected using both MRI and single-sided MR.
Device-based sensing was successful in hCG solutions from 0.1 to 5 tg hCG/mL. Devices made
with 10 nm pore membranes need approximately four days to reach the maximum decrease in
T2,eff, for the analyte and MRSw concentrations used in these experiments. Devices with 30 nm
pore membranes demonstrate a faster decrease in T2,ff, but the aggregates are less stable. Results
from these in vitro experiments were used to design the in vivo sensing experiments described in
Chapter 6. Future studies should be performed to determine what causes the increase in T2,eff
observed in the devices placed in hCG solutions. Particle size data could be used to determine if
the increase in T2,effiS caused by aggregates growing so large that they precipitate out of solution.
This would require the volume of the reservoirs to be doubled, since the current devices do not
hold enough MRSw solution for particle sizing.
Chapter 6 In Vivo Sensing Experiments
6.1 Summary
An implantable diagnostic device capable of sensing the local in vivo environment has
been developed. The device uses a semi-permeable membrane to contain nanoparticle magnetic
relaxation switches (MRSw). We have used this proof-of-principle device to detect a soluble
cancer biomarker in a mouse model. A cell line secreting a model cancer biomarker was used to
produce ectopic tumors in nude mice. The device was implanted subcutaneously, and magnetic
resonance imaging (MRI) and single-sided magnetic relaxometry (MR) were used to read the
device. The transverse relaxation time (T2) of devices was 38 +/- 1 ms in control mice versus 28
+/- 3 ms in tumor-bearing mice at one day by MRI (p < 0.001). This trend was also observed at
day four by MRI and upon explantation by single-sided MR. This device may be the first
continuous monitoring device for cancer that can be implanted at the tumor site and demonstrates
feasibility of MRSw measurements in vivo. Future research may use such devices for the
development of new therapeutic agents and evaluation of targeted delivery modalities. They
may also enable real-time personalized cancer treatment, featuring long-term tracking of
treatment and monitoring of local reoccurrence with a single implant.
6.2 Introduction
There are many clinical scenarios in cancer therapy where sampling of the local tissue
environment at the tumor site would be beneficial. A patient that has undergone tumor resection
would benefit, for example, from sampling of fluids to confirm that all of the neoplastic tissue
has been removed. Alternatively, a patient with an inoperable tumor would be able to have
repeated fluid sampling at the tumor site to determine if the administered chemotherapeutic
agents were actually reaching the tumor. Sampling the local environment, however, currently
requires a surgical procedure such as another biopsy. We have constructed and tested a
diagnostic device that could be left behind during a tumor resection and periodically monitored
with MRI to provide information about the local environment. Data collected from the sensor
device would aide the physician in determining whether another surgical resection or
chemotherapy treatment was necessary.
Proof-of-principle in vivo sensing experiments were performed using high density
polyethylene (HDPE) devices cup-shaped devices (Section 2.3.3). Mice were divided into two
main groups: with a tumor (n = 34) and without a tumor (n = 11). Mice with tumors received one
device, implanted subcutaneously near the tumor site once the plasma hCG concentrations began
increasing. Mice without tumors received two devices, one on each flank. All the devices were
filled with the same concentration of MRSw functionalized to detect hCG, non-functionalized
MRSw, or MRSw functionalized to detect IL-2, a chemotherapeutic agent. Figure 6-1
summarizes the different groups for device-based in vivo sensing.
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Figure 6-1. Experimental plan for device-based in vivo sensing.
6.3 Materials and Methods
6.3.1 Device Fabrication
Cup-shaped devices were used for in vivo sensing experiments since they are more robust
than the PDMS and washer devices. See Sections 2.3.2 and 2.4.2 for details about device
fabrication. Devices were filled with non-functionalized MRSw, MRSw functionalized to detect
hCG, or MRSw functionalized to detect IL-2, a chemotherapeutic agent. The non-functionalized
MRSw and MRSw functionalized to detect IL-2 were added to ensure that any decrease in T2
seen with MRSw functionalized to detect hCG was in fact due to hCG induced aggregation.
6.3.2 Tumor Induction
Two commercially available human cell lines that secrete hCG and are tumorigenic in
mice were considered: JAR (ATCC) and JEG-3 (ATCC). The cells were propagated and
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subcultured according to the manufacturer's instructions until the time of tumor induction. The
cells were then harvested and counted with a particle counter (Beckman Zi Coulter Particle
Counter) to determine the cell concentration. The cells were washed three times and re-
suspended in sterile PBS to a concentration of 107 cells/mL. Equal volumes of cell solution and
growth factor reduced MatrigelTM matrix (BD Biosciences) were mixed together. Mice were
anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg).
A 16 gauge needle was tunneled subcutaneously from the shoulder to the flank of the mouse, and
200 jiL of the cell mixture was slowly injected (total of 106 cells per mouse) in the flank of each
female NCr nude mouse (Taconic) (n = 34). The skin around the needle tip was compressed and
held while the needle was removed and for the next 30-45 s to allow the cell solution to solidify
as a depot. Control mice (no tumors, n = 11) underwent the same subcutaneous injection
procedure on both flanks, with a solution of equal volumes of sterile PBS and MatrigelTM .
Retroorbital bleeding was performed periodically after tumor induction. Mice were anesthetized
with continuous 1-4% isoflurane/oxygen inhalation, and the blood was collected in serum gel
tubes (Sarstedt). The samples were centrifuged at 13,000 rpm for 5 minutes and then frozen for
later analysis. Plasma hCG concentrations were determined using an ELISA kit (United Biotech
Inc). The assay was performed according to the manufacturer's instructions using dilutions as
necessary in the provided assay buffer. All work involving mice was performed according to the
policies of the Massachusetts Institute of Technology Committee on Animal Care. Mice were
housed in autoclaved cages and had access to autoclaved food and water ad libitum.
6.3.3 Device Implantation
Two different in vivo sensing experiments were conducted. In one experiment, devices
were implanted subcutaneously and the incision was allowed to heal for 9 or 14 days before
injection of MatrigelTM/cell solution or MatrigelTM/PBS solution (see Section 6.3.2). Devices
were explanted 12 or 15 days after tumor induction. This experiment was designed to mimic an
application where the analyte being detected is not present at the time of device implantation.
The other experiment tested short term in vivo sensing: tumor cells were injected and device
implantation was performed when a sharp increase in either tumor size or plasma hCG
concentration was observed, between 13 to 19 days after tumor cell injection. Control devices
were implanted around the same time as sample devices. Devices were explanted two to four
days after implantation. Figure 6-2 is a schematic of the schedule for the two sensing device-
based sensing experiments.
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Figure 6-2. Schedule for in vivo sensing experiments. a) Device-based sensing where the device is implantedbefore the analyte is present. Devices were implanted for a total of 21 to 29 days. b) Short term device-based
sensing experiment with devices implanted for four days.
For device implantation, mice were anesthetized with an intraperitoneal injection of
ketamine (100 mg/kg) and xylazine (10 mg/kg). Preemptive analgesics (buprenorphine, 0.1
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mg/kg) were administered subcutaneously before the first incision. Mice with tumors (n = 34)
received a dorsal midline incision, and blunt dissection was used to tunnel subcutaneously to the
tumor site and create a pocket for the device. Mice without tumors (n = 11) also received a dorsal
midline incision and blunt dissection was used to create a pocket on each flank (two devices per
mouse). All devices were placed in the pocket with the membrane facing the muscular layer and
the incision was closed with silk sutures. Mice were monitored daily for signs of distress,
infection, or excessive tumor burden.
6.3.4 NMR Relaxometry Measurements
Two techniques were used to quantify the transverse relaxation time of the MRSw in the
device: MRI (reported as T2) and single-sided MR (reported as T2,eff). A benefit of MRI is that it
allows for live animal imaging, so the same device can be imaged multiple times. Single-sided
MR requires the device to be explanted, so the T2,eff can only be quantified at one time point
using this technology. MRI is more time and cost-intensive than single-sided MR, however, so a
subset of animals were chosen for MR imaging, while all devices were analyzed with single-
sided MR. MR imaging was performed one day and four days after device implantation. Four of
the mice had tumors, two did not have tumors. Mice without tumors received a device on each
flank, so there were four devices in each group. The imaging time points were chosen based
upon the measured Papp of hCG through the polycarbonate membrane and the kinetics of
aggregation for the MRSw. The analyte concentration in the reservoir was calculated to be more
than 95% of the equilibrium concentration at one day44. This calculation assumes an infinite
source of hCG, meaning that the concentration of hCG outside the reservoir remains constant.
The infinite source assumption may not be valid in vivo and the time required to reach an
equilibrium concentration may increase. The kinetic behavior of MRSw aggregation is another
factor that could increase the time needed to see a decrease in T2, as it continues to decrease for
approximately 24 hours after mixing the analyte and MRSw solutions (Figure 4-5). The imaging
session on day four was selected to allow for longer diffusion and aggregation times.
Mice scheduled for MR imaging were transported to the Center for Molecular Imaging
Research (CMIR) at Massachusetts General Hospital (MGH) after they awoke from anesthesia
from the device implantation surgery (n = 6). They were imaged on day one and day four post
device implantation, and subsequently transported to MIT so the devices could be explanted and
measured on the single-sided MR. MRI was performed at 7 T on a Bruker imaging system
(Pharmascan). Animals were anesthetized during imaging with 1-1.5% inhaled isoflurane, and
monitored during imaging with respiratory monitoring. Imaging protocols included a Tri-plane
and axial RARE localizer. Multi-slice multiecho (MSME) T2-weighted imaging was performed
utilizing the following parameters: Flip angle = 900; Matrix size (128 x184); TR = 2330 ms.; TE
= 16 equally spaced echoes at 8.8 ms intervals ranging from 8.8 ms to 141 ms; field of view
(FOV) = 4 x 4 cm, slice thickness = Imm. Ti-weighted imaging was performed utilizing the
following parameters: Flip angle = 900; Matrix size (192 x 256); TR = 700 ms; TE = 14 ms; field
of view (FOV) = 4 x 4 cm, slice thickness = lmm. Region of interest analysis was performed and
T2 fit by using a mono-exponential fitting algorithm for the multi-TE data (Osirix). ROI
incorporating the center 2-3 slices of the device were analyzed. The fitting of the T2 was
modified by subtracting the mean background noise, and only points above this mean baseline
threshold were used for the fit.
In the first sensing experiment, all devices were explanted two to four days post
implantation and a T2,eff measurement was immediately made using a single-sided NMR probe
(Profile NMR MOUSE, ACT Center for Technology, Aachen, Germany). In the second sensing
experiment, all devices were explanted 12 to 15 days after tumor induction and immediately
measured on the single-sided MR. The explanted devices were individually positioned over the
sensitive volume. The sensitive volume of the probe was located 2 mm above the center of the
probe surface. The probe has a field strength of 0.43 T and a static field gradient of 15 mT/mm.
It was maintained at 250C using a circulating water bath. The similarity in magnitude between
T2 measured by MRI and T2,eff measured by single-sided MR is coincidental. A Minispec
spectrometer (Bruker Optics) was used for pulse sequence generation and data acquisition. T2,eff
was measured using a 2000-echo CPMG pulse sequence with TE = 0.035 ms and TR = 1 s. The
data were averaged over 48 scans. The measurements took approximately one minute per
sample. The echo peak intensities were fit to the equation
I = Ioe (6-1)
using a custom script running on MATLAB (The Mathworks).
6.4 Results and Discussion
6. 4.1 Tumor Induction
The two cell lines (JAR and JEG-3) were used to induce ectopic tumors in mice. Figure
6-3 shows the plasma hCG-b concentrations in eight mice (four for each cell line). The JAR cell
line is represented by blue dashed lines and the JEG-3 cell line by solid pink lines. The plasma
hCG-b concentrations of the mice with the JAR cells ranged from 0.13 to 0.95 gtg hCG-b/mL 18
days after tumor induction. Plasma concentrations of mice with JEG-3 cells, however, were
between 0.34 and 0.64 gLg hCG-b/mL on day 18. JEG-3 cells were chosen for tumor induction in
the in vivo sensing experiments because they seemed to produce more consistent plasma hCG-b
concentrations.
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Figure 6-3. Plasma hCG-b concentrations in mice from ectopic tumors induced by two different cell lines:JAR (dashed blue lines) and JEG-3 (solid pink lines). A commercially available ELISA was used to quantify
hCG-b levels in plasma samples.
6.4.2 Device-based sensing: Single-sided MR detection
Devices were filled with MRSw functionalized to detect hCG (Cmix-3000, 8 pg Fe/mL)
and implanted in 12 mice. Mice scheduled to undergo tumor induction received one device on
the flank. Mice scheduled to undergo control injections received a device on each flank. Nine
days after device implantation, six mice received injections near the device (two control mice,
four sample mice). The remaining six mice received injections 21 days after device implantation
(two control mice, four sample mice). Sample mice received an injection of Matrigel TM and JEG-
3 cells next to the device. The JEG-3 cells were washed three times prior to injection to ensure
removal of any hCG that was present in the media. Control mice received control injections
(MatrigelTM and PBS) at each device. Devices were explanted 12 or 15 days later, depending on
tumor size and the T2,eff of the devices quantified using single-sided MR. Figure 6-4 shows the
T2,eff for each device after being explanted. Figure 6-4a shows the results for devices that were
implanted a total of 21 to 24 days. There is no significant difference (p = 0.06) between the
control devices on the left (T2,eff = 41.9 +/- 0.6 ms) and the sample devices on the right (T2,ef =
41.2 +/- 0.5 ms). Figure 6-4b shows the results for devices that were implanted a total of 26 to 29
days. There is no significant difference (p = 0.4) between the four control devices on the left
(mean T2,eff= 42 +/- 1 ms) and the four sample devices on the right (mean T2,eff = 42 +/- 1 ms).
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Figure 6-4. Results for device-based in vivo sensing where devices are implanted before the analyte is present.
Single-sided MR was used to detect MRSw aggregation. a) T2,eff measurements for devices that were
implanted for a total of 21 to 24 days (nine days before tumor induction, 12 or 15 days after tumor induction).
b) T2,eff measurements for devices that were implanted for a total of 26 to 29 days (14 days before tumor
induction, 12 to 15 days after tumor induction).
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The lack of a decrease in T2,eff could be caused by several different factors. It is possible
that the devices began to leak after being implanted for three to four weeks, and any decrease in
T2,eff is masked by an increase in T2,ff due to the MRSw leak. It is also possible that the MRSw in
devices implanted next to the tumors did aggregate and cause a decrease in T2,eff. The T2,eff then
began to increase, either because of the prozone effect or insolubility of large aggregates, and by
the time the devices were explanted and read there was no longer a significant difference
between the control and sample devices. This problem would easily be solved by using live
animal MRI imaging to quantify the T2,eff in the devices at several points during the experiment.
Matrix stabilization could also be added to the MRSw in the devices. This would prevent the
aggregates from precipitating out of solution, resulting in a stable T2,f53. A third possible
explanation for the behavior seen in this sensing experiment is that the MRSw were not able to
aggregate in the presence of hCG after being implanted in vivo for 9 to 14 days before tumor
induction. Section 4.5 discusses some techniques that may be able to improve the stability of the
antibodies on the MRSw surface.
6. 4.3 Short term device-based sensing: MRI detection
Short term sensing experiments were able to detect the presence of hCG in vivo. In these
experiments, tumors were started first, and devices were implanted next to the tumor once the
tumor size or plasma hCG levels began to increase sharply. Devices were explanted two to four
days later. Six mice (two control, four sample) underwent live animal MRI imaging on day one
and four after device implantation. Figure 6-5 is an example of the type of MRI images obtained.
Superimposed over each device is a pseudo-colorized map that represents the T2 within the
device. The T2 of the control device did not change from day one (Figure 6-5a) to day four
(Figure 6-5b) indicating that the MRSw were well contained within the reservoir by the
polycarbonate membrane. The T2 of the device implanted near a tumor decreased from day one
(Figure 6-5c) to day four (Figure 6-5d) and was lower than the control device on both days. This
indicates that hCG was secreted by the tumor, diffused into the devices, and caused aggregation
of the MRSw. Calculations based on the Papp for hCG with these membranes predicted the
concentration inside the reservoir to be more than 95% of the equilibrium concentration by the
first MRI time point.
Figure 6-5. TI-weighted in vivo MR images for a control (a and b) and tumor (c and d) device. Superimposed
over the device is a pseudo-colorized map of the T2 within the device (color bar on the left). The control device
showed no change in T2 from day one (a) to day four (b). The T2 of the sample device decreased from day one
(c) to day four (d) and was lower than the control device on both days.
Figure 6-6 shows the T2 for each device at each MRI time point. The T2 of the control
devices (no tumor present) were approximately constant over the two imaging time points. T2 of
the sample devices were all lower than the control devices on day one and an even larger
decrease in T2 was observed on day four. The mean T2 of the control devices (n = 4) was 38 +/- 1
ms on day one and 37 +/- 2 ms on day four. The mean T2 of the sample devices (n = 4) was 26
+/- 4 ms on day one and 20 +/- 2 ms on day four. The decrease in T2 of the sample devices
compared to the control devices is statistically significant (Student's t-test, one tail, equal
variances) for both time points (p = 0.001 day one, p = 3x10-6 day four).
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Figure 6-6. T2 values for each device in the short term device-based sensing experiment that was sent for MR
imaging. Imaging took place one day (blue columns) after device implantation and again four days (green
columns) after device implantation.
6.4.4 Short term device-based sensing: Single-sided MR detection
Immediately after the second MRI time point, the six mice were transported back to MIT,
the devices were explanted, and the T2,eff was quantified by single-sided MR. This allowed the
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results from the single-sided MR to be verified by MRI. Figure 6-7 compares the percent change
in T2 or T2,eff, compared to the average value of the control devices (Equation 5-2), for the four
sample devices. The magnitude of the percent change in T2 is greater for MRI analysis, as
expected. The two measurement techniques reveal the same trend, though. Tumor 1 is the
smallest percent change for both measurement techniques, while there is little difference between
the other three devices. These results verify that explanting devices to be read on the single-sided
MR is a valid method of detecting MRSw aggregation for in vivo sensing experiments.
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Figure 6-7. Comparison of single-sided MR (blue columns) and MRI (purple columns) results from shortterm device-based sensing experiment. Values are reported as a percent change in T2,eff, compared to controldevices that were placed in PBS solutions.
Single-sided MR was used to measure the T2,eff of all the remaining in vivo devices at
explantation. Furthermore, devices filled with non-functionalized MRSw and devices filled with
MRSw functionalized to detect IL-2 (a chemotherapeutic agent) were implanted in mice with
and without tumors as additional controls. These controls were to test that the decrease in T2,eff
I I I
• 
Single-sided 
MR
•MRI
seen in devices filled with MRSw functionalized to detect hCG and implanted near a tumor site
was indeed due to the presence of hCG, not some other effect of implantation near the tumor.
Figure 6-8 shows the mean T2,ff of each group as quantified by single-sided MR. Only mice with
tumors and devices filled with MRSw functionalized to detect hCG showed a statistically
significant (p = 3x10-10) decrease in T2,eff (33 +/- 2 ms, n = 19) compared to the same MRSw in
devices implanted in mice without tumors (T2,eff = 37.6 +/- 0.3 ms, n = 8). There was no
statistically significant difference (p = 0.3) in T2,eff between the control devices (T2,e = 39.0 +/-
0.6 ms, n = 6) and sample devices (T2,ff = 38.9 +/- 0.5 ms, n = 8) when the devices were filled
with non-functionalized MRSw. There was also no statistically significant difference (p = 0.08)
in T2,eff between the control devices (T2,eff =37.4 +/- 0.5 ms, n = 8) and sample devices (T2,eff =
37.9 +/- 0.7 ms, n = 7) when the devices were filled with MRSw functionalized to detect IL-2.
Thus, the decrease in T2,eff is caused by hCG induced aggregation of the nanoparticles
functionalized to detect hCG.
Figure 6-8. Summary of short term sensing results using single-sided MR detection. Only devices filled with
MRSw functionalized to detect hCG and implanted next to a tumor showed a significant decrease in T2,eff.
Figure 6-9 shows T2,eff readings for each short term in vivo sensing device. In each figure,
the control devices (implanted in mice with no tumors) are on the left and the tumor devices
(implanted in mice with tumors) are on the right. Figure 6-9a shows the data for devices filled
with MRSw functionalized to detect hCG. All the tumor devices have a T2,eff that is significantly
lower than the control devices, but the magnitude of the T2,eff decrease varies significantly
between mice. Figure 6-9b (devices filled with non-functionalized MRSw) and Figure 6-9c
(devices filled with MRSw functionalized to detect IL-2) show that there is no significant
difference between the control and tumor devices for these MRSw.
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Figure 6-9. T2,eff readings for each short term in vivo sensing device. a) Devices filled with MRSwfunctionalized to detect hCG, b) devices filled with non-functionalized MRSw, and c) devices filled withMRSw functionalized to detect IL-2.
The variation in T2,eff amongst tumor devices in Figure 6-9a is most likely due to differing
concentrations of hCG at the device location. Plasma samples were taken at the time of device
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implant and explant, and hCG plasma concentrations were quantified with an ELISA kit. These
concentrations were used to estimate the device exposure to hCG from the area under the curve
(AUC) of a plasma concentration vs time plot. Figure 6-10 shows that the in vivo devices work
very well as "switches". Every device that was exposed to hCG from the tumor demonstrated a
decrease in T2,eff compared to control devices. The AUC of hCG calculated from plasma levels,
however, did not correlate with the magnitude of decrease in T2,eff. This is not surprising as
systemic concentrations are not expected to accurately reflect the local concentration
experienced by the device. The size of the mouse model was prohibitive for obtaining the local
hCG concentration in the extracellular space. Even if we had an accurate measure of the hCG
concentration at the device location, though, Figure 5-8 and Figure 5-11 show that during in vitro
sensing experiments the magnitude of the decrease in T2,eff does not always correlate with the
concentration of the analyte bath. In vivo devices that show a smaller decrease in T2,ff at day four
could have gone through a minimum in T2,eff at an earlier time and then a gradual T2,eff increase
due to instability of the aggregates.
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Figure 6-10. Percent change in T2,,ff (compared to control devices) as a function of device exposure to hCG,
calculated from the AUC of a plasma hCG concentration vs time plot. There is no correlation between the
magnitude of the percent change in T2,eff and the AUC calculated from plasma hCG concentrations. This is
not surprising, since plasma hCG levels are not expected to accurately reflect hCG concentrations at the
tumor location.
6.5 Conclusion
This work demonstrates the feasibility of MRSw-based devices for short term
applications, such as verification of successful tumor resection, and represents the first
continuous monitoring device of soluble cancer biomarkers in vivo. The device described here
could also be used for in vivo sensing of chemotherapeutic agents or metabolites simply by
changing the MRSw contained within the device. In vivo performance was assessed using a
commercially available human epithelial cell line (JEG-3) to produce ectopic tumors that secrete
hCG in nude mice. Plasma hCG-b concentrations were quantified with an enzyme-linked
immunosorbent assay (ELISA). Implantation was performed when the plasma hCG-b
concentrations or tumor volume began to increase sharply. Six mice underwent live animal
imaging by MRI one day and four days after device implantation to quantify T2 of the MRSw.
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All devices were measured using single-sided MR after they were explanted (two to four days
after implantation). Only devices that were filled with MRSw functionalized to detect hCG and
implanted next to a tumor demonstrated a decrease in T2,eff.
Long term use of such implanted sensing devices will require demonstration of in vivo
stability for periods exceeding one month. Future studies in a larger animal model will test the
correlation between local hCG concentrations from repeated needle biopsy with each MRI
measurement. Future studies will also incorporate the high porosity nano-channel membranes.
These membranes with a higher Papp will decrease the time needed for diffusion of the analyte,
allowing for real time monitoring of biomarkers and chemotherapeutic agents.
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Chapter 7 Polymer Microchip for Drug Delivery
7.1 Summary
A syringe-injectable drug delivery device has been developed. This format will allow
minimally invasive implantation of the device through a large-bore needle or trocar. In vitro
release studies show that the new syringe-injectable format can achieve similar release profiles
as the original dime-shaped polymer drug delivery device. A resorbable sealing method has been
developed for the polymer microchip. Solvent welding at room temperature was able to achieve
a leak proof seal for 14 days. This new sealing method makes the polymer microchip completely
resorbable and eliminates the need to remove the device after delivery of the drug payload.
7.2 Introduction
Local delivery of multiple chemicals has been demonstrated from a resorbable polymeric
microchip' 6 (passive device). The microchips contain small reservoirs that are loaded with drug
and separated from the outside environment by a polymer membrane on the front of the
microchip and pressure sensitive adhesive on the back of the microchip. The composition,
molecular weight, and thickness of the polymer membranes determine when the membrane will
degrade and release the drug depot from the reservoir 16. This polymer microchip has
demonstrated in vitro16,'18 and in vivo53,56 release of multiple compounds.
One limitation of the current polymer microchip is the device size and shape. If the
current passive microchip format were used for treatment of a brain tumor, surgery would be
required for tumor resection and implantation of the device. Therefore, this application is limited
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to tumors that are accessible via surgery and that are large enough to leave room for placement
of the microchip after tumor resection. A smaller microchip might decrease the trauma
experienced by the surrounding (healthy) tissue and allow treatment of unresectable and/or small
tumors that would otherwise not be treatable with the current device. The fabrication process of
the passive chip is very flexible and could easily be modified to produce a device of nearly any
size or shape. Of particular interest would be a thin cylindrical device, which would allow
minimally invasive implantation techniques to be used, such as injection with a trocar or large-
bore needle. Figure 7-1 is a schematic of the injectable format polymer microchip. Norplant®
capsules (subdermal implants for long-acting contraception) are cylindrical in shape with a
diameter of 2.4 mm and length of 34 mm5 7. The standard implantation protocol for these
capsules is injection using a #10 trocar under local anesthesia". Since the injectable polymer
microchip will have a diameter that is nearly half the Norplant® diameter, a large-bore needle or
trocar should also be able to implant the new device. This format change would also make the
passive microchip more applicable in diverse treatments such as vaccination or hormone therapy
treatment.
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Figure 7-1. Schematic of an injectable polymer microchip for localized drug delivery. Removal of the device
after it has delivered the payload is not required if the polymer substrate and membranes are resorbable.
Another limitation of the polymer microchip is that it is not fully biodegradable. The
current sealing method (a non-resorbable polymeric pressure sensitive adhesive) creates an
effective, leak-proof seal' 8 but requires surgical removal once the device has released its
payload. The new sealing layer must be biodegradable, biocompatible, prevent leakage of the
drug depot, and retain the activity of the loaded drug.
7.3 Materials and Methods
7.3.1 Syringe-Injectable Format
Polymer microchip devices were fabricated as previously described' 6 . Injectable format
devices (a lx6 array of reservoirs) were cut from the regular polymer microchip devices using a
hot razor blade. The razor blade was heated by placing it on a hot press (3700 F) for 30 seconds
and then it was immediately used to cut the PLA substrate by pressing down on the blade. The
dimensions of the injectable microchip are approximately 1.5 x 0.5 x 12 mm. PLGA 2A
membranes (inherent viscosity of 0.16, Lakeshore Biomaterials, Birmingham, AL) were added to
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the reservoirs as previously described 6. A solution of radiolabeled dextran (14 C-dextran, 40 kDa,
Sigma-Aldrich, St. Louis, MO) was microinjected into the reservoirs and the back of the devices
was sealed with a pressure sensitive adhesive.
Some of the injectable format devices underwent a mock implantation step. A 12 gauge
needle was inserted into an agarose hydrogel, the plunger was removed, and the injectable format
device was loaded into the barrel of the needle. The plunger was used to advance the device to
the tip of the needle, then the plunger was held stationary while the needle was withdrawn,
leaving the device behind in the hydrogel. The device was carefully removed from the hydrogel
and placed in one mL of PBS at 370C. Injectable format control devices were immediately placed
in one mL of PBS at 370C, without undergoing a mock implantation step. Regular format
polymer microchips were also used as control devices and were placed directly in one mL of
PBS at 370C after fabrication, loading, and sealing. The PBS was removed periodically and
combined with five mL of scintillation fluid (ScintiSafe Plus 50%, Fischer Chemicals, Fairlawn,
NJ) in a scintillation vial. A counting protocol for 14C was used on a Packard Tri-Carb liquid
scintillation counter (Perkin Elmer, Waltham, MA). Raw data (disintegrations per minute, DPM)
was converted to nanocuries (nCi) using the conversion factor 2,200 dpm = 1 nCi.
7.3.2 Resorbable Sealing Mechanism
Polymer microchip devices were fabricated as previously described 16. A PLA (100L
PLA, 200 kDa, Lakeshore Biomaterials, Birmingham, AL) backing layer was prepared using the
same fabrication process as for the polymer microchip, except the aluminum die used in the hot
press step did not contain any conical protrusions. The PLA backing layer was approximately
500 pm thick after polishing. The microchip devices were covered with pressure sensitive
adhesive (Ideal 9144, American Biltrite, Lowell, MA) on the front and the reservoirs filled with
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radiolabeled dextran (14C-dextran, 40 kDa, Sigma-Aldrich, St. Louis, MO). Approximately 70
jiL of either PLA or PCL dissolved in chloroform (12%, v/v) was microinjected around the
reservoirs on the back side of the polymer microchip. The PLA backing layer was placed on top
of the microchip, held in place with a small weight (approximately 10 g) and allowed to dry at
room temperature overnight. The devices were then placed in five mL of PBS at 370 C. Control
devices with pressure sensitive adhesive on both side of the microchip were also placed in five
mL of PBS at 370C. The five mL of PBS was periodically transferred to a scintillation vial with
15 mL of scintillation fluid (ScintiSafe Plus 50%, Fischer Chemicals, Fairlawn, NJ) and five mL
of fresh PBS was added back to the container holding the microchip device. Time points were
taken for two weeks. A counting protocol for 14C was used on a Packard Tri-Carb liquid
scintillation counter (Perkin Elmer, Waltham, MA).
7.4 Results
7.4.1 Syringe-injectable format
Injectable format control devices (no mock implantation step) were first tested in release
experiments. The cutting process during fabrication of the injectable format device could create
micro-cracks in the reservoir wall, resulting in immediate release of the loaded drug through the
side of the reservoir. The injectable format also has less surface area on the back for sealing with
the pressure sensitive adhesive which could lead to less reliable device performance. Figure 7-2
shows that the release profile from the injectable format control devices (1x6 arrays of
reservoirs) (blue diamonds) is comparable to the release profile from the regular format polymer
devices (pink squares). These results show that the injectable format device is capable of the
same controlled release profiles as the regular polymer microchip.
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Figure 7-2. Release profiles from injectable format control devices (n = 6, no mock implantation step) and
regular format microchip devices (n = 2). Both device types contain PLGA 2A membranes.
The injectable format devices were also used in release experiments after undergoing a
mock implantation step. Mechanical stresses during the implantation process could damage the
polymer membranes, causing immediate release of the drug payload instead of a delayed release
after degradation of the polymer membranes. Figure 7-3 shows the release profile for three
injectable format devices that went through a mock implantation step and the average release
profile for injectable formal control devices (n = 3, no mock implantation step). The drug
payload of all devices was expected to be released between two to four days. Figure 7-3 shows
that there was significant variability in the behavior of the injectable format devices that
underwent a mock implantation step. These devices did not, however, show immediate release of
the payload as would be expected if the implantation procedure damaged the membranes.
Variability of this type is relatively common with the passive polymer microchip. The variability
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in the release behavior of the devices could be caused by small differences in the device substrate
(reservoir diameter, air bubbles in the device substrate) or membrane (thickness of reservoir
membrane).
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Figure 7-3. Release profile for injectable format devices that have undergone a mock implantation step.
7.4.2 Biodegradable sealing method
Room temperature solvent welding has been used to create a resorbable seal between the
polymer microchip and a PLA backing layer. Figure 7-4 shows that while the seal from PCL
solvent welding failed after approximately five days, the seal from PLA solvent welding was still
intact after 14 days (less than 5% of the loaded drug had leaked). Less than 2% of the loaded
drug had leaked from the control devices (pressure sensitive adhesive on both sides of the
device) after 14 days. A resorbable seal lasting 14 days would be appropriate for some local drug
delivery applications.
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Figure 7-4. Leak test for resorbable sealing mechanism using solvent welding technique. Error bars represent
st. dev. (n = 2 for each group).
7.5 Summary
Preliminary studies were performed in the development of a syringe-injectable drug
delivery device. The injectable format was shown to be able to achieve delayed release of a
loaded drug payload, even after going through a mock implantation step. Preliminary work was
also done towards developing a completely resorbable polymer microchip. Solvent welding with
PLA in chloroform was able to adhere a PLA backing layer to the substrate for 14 days. Less
than 5% of the loaded drug leaked out during this time frame, compared to less than 2% leaking
out of control devices (pressure sensitive adhesive on both sides of the reservoir). A 14 day seal
is an appropriate time frame for some local drug delivery applications, but future studies will
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need to be done to develop a resorbable sealing method that would be appropriate for long term
localized drug delivery applications.
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Chapter 8 Conclusions and Future Directions
8.1 Conclusions
This thesis includes several important first steps in the development of an implantable
cancer sensor. This sensor device combines the polymer microchip drug delivery platform with
magnetic relaxation switch (MRSw) nanoparticle sensors. MRSw are magnetic nanoparticles
(iron oxide core, crosslinked dextran shell) that can detect a variety of analytes. MRSw are kept
in the device by a molecular weight cut-off (MWCO) membrane which allows analytes free
access to the nanoparticle sensors. The MRSw aggregate in the presence of the analyte they were
designed to detect and this aggregation causes a decrease in the transverse relaxation time (T2),
which can be detected with magnetic resonance imaging (MRI) or nuclear magnetic resonance
(NMR) relaxometry. In vitro sensing experiments were used to optimize the device design and
characterize its performance. In vivo device-based sensing of hCG, a soluble biomarker that is
elevated in testicular and ovarian cancer, has been demonstrated. The polymer microchip drug
delivery device was also modified to a syringe-injectable format which will allow minimally
invasive implantation through a large-bore needle or trocar. In vitro release studies show that the
new syringe-injectable format can achieve similar release profiles as the original dime-shaped
polymer drug delivery device. A resorbable sealing method has been developed for the polymer
microchip. Solvent welding at room temperature was able to achieve a leak proof seal for 14
days. This new sealing method makes the polymer microchip completely resorbable and
eliminates the need to remove the device after delivery of the drug payload.
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8.1.1 Sensor Device Fabrication
Several different device designs were made and tested. The most reliable design is a cup-
shaped device made from HDPE, with a 5 mm diameter and 2.5 mm deep reservoir. Double-
sided pressure-sensitive adhesive is used to adhere a polycarbonate membrane to the device
substrate. MRSw are added to the reservoir through a filling port on the back of the device which
is then sealed with pressure sensitive adhesive. This device design has proven to be very reliable
for the in vitro and in vivo studies carried out to date.
8.1.2 Characterization ofMWCO Membranes
Several commercially available membranes were identified that are able to both retain
MRSw and allow analyte diffusion. Analyte diffusion times, around 24 hours to reach
equilibrium, are reasonable for an in vivo cancer sensor device. The effect of biomolecule
adsorption on polycarbonate membranes was tested in an animal model. The diffusion of dextran
(40 kDa) does not change significantly after the membranes have been implanted for up to one
month. High porosity nano-channel membranes, made in the Cima group, were also tested.
These membranes were able to retain MRSw functionalized to detect hCG. The apparent
permeability of hCG through the nano-channel membranes is about two orders of magnitude
higher than for commercially available polycarbonate membranes (10 nm pores).
8.1.3 Characterization ofMRSw Aggregation
The batch of MRSw referred to as Cmix-3000 was found to retain activity after being
stored at 40C for seven months. Much of the activity of Cmix-3000 was lost, however, after
incubation at 370C for one month. The MRSw were still able to aggregate, but the operating
range of hCG concentrations was significantly smaller and the decrease in T2,eff was less
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pronounced. Stability of aggregates was found to be a function of both MRSw valency and hCG
concentration, as expected. Cmix-3000 was found to form stable aggregates for a range of hCG
concentrations relevant to in vivo experiments and this batch of MRSw was used for many
device-based sensing experiments.
8.1.4 In Vitro Device-Based Sensing
Multiple in vitro sensing experiments have demonstrated the ability to detect the presence
of hCG using MRSw that are contained within a reservoir by a semi-permeable membrane.
Aggregation of the MRSw within the device was detected using both MRI and single-sided MR.
Device-based sensing was successful in hCG solutions from 0.1 to 5 jig hCG/mL. Devices made
with 10 nm pore membranes need approximately four days to reach the maximum decrease in
T2,eff, for the analyte and MRSw concentrations used in these experiments. Devices with 30 nm
pore membranes demonstrate a faster decrease in T2,ff, but the aggregates are less stable.
8.1.5 In Vivo Device-Based Sensing
This work demonstrates the feasibility of MRSw-based devices for short term
applications, such as verification of successful tumor resection, and represents the first
continuous monitoring device of soluble cancer biomarkers in vivo. In vivo performance was
assessed using a commercially available human epithelial cell line (JEG-3) to produce ectopic
tumors that secrete hCG in nude mice. Plasma hCG-b concentrations were quantified with an
enzyme-linked immunosorbent assay (ELISA). Implantation was performed when the plasma
hCG-b concentrations or tumor volume began to increase sharply. Six mice underwent live
animal imaging by MRI one day and four days after device implantation to quantify T2 of the
MRSw. All devices were measured using single-sided MR after they were explanted (two to
113
four days after implantation). Only devices that were filled with MRSw functionalized to detect
hCG and implanted next to a tumor demonstrated a decrease in T2,eff.
8.1.6 Polymer Microchipfor Drug Delivery
Preliminary studies were performed in the development of a syringe-injectable drug
delivery device. The injectable format was shown to be able to achieve delayed release of a
loaded drug payload, even after going through a mock implantation step. Preliminary work was
also done towards developing a completely resorbable polymer microchip. Solvent welding with
PLA in chloroform was able to adhere a PLA backing layer to the substrate for 14 days. Less
than 5% of the loaded drug leaked out during this time frame, compared to less than 2% leaking
out of control devices (pressure sensitive adhesive on both sides of the reservoir). A 14 day seal
is an appropriate time frame for some local drug delivery applications.
8.2 Future Directions
8.2.1 Sensor Device Fabrication
Long term device reliability will need to be demonstrated for many clinical applications,
such as detection of cancer recurrence. One likely source of device failure in longer term sensing
experiments is the seal between the device substrate and the MWCO membrane. A mechanical
means of attaching the MWCO membrane to the device substrate, such as two plastic pieces that
are machined to fit snugly together while holding the membrane in place between them, may
improve the long term reliability of the device. Future device designs should also use the high
porosity nano-channel membranes. These membranes with a higher Papp will decrease the time
needed for diffusion of the analyte, allowing for real time monitoring of biomarkers and
chemotherapeutic agents.
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8.2.2 MWCO Membranes
Future studies should examine the effects of longer implantation times and fibrous
capsule formation on membrane biofouling and analyte transport. Recent work with a silicon
device gives promising evidence that a fibrous capsule may not significantly hinder protein
transport up to 6 months in beagle dogs 52 . Previous research has shown that permeability of
polycarbonate membranes in vivo can be enhanced by plasma surface treatment45. We will
explore this technique if in vivo transport kinetics vary significantly from in vitro results after
longer implantation times.
8.2.3 MRSw Aggregation
The ability to perform long term in vitro and in vivo sensing experiments depends on
MRSw that retain activity when stored at 370 C and produce stable aggregates. Previous work has
demonstrated that stabilization of MRSw aggregates can be achieved by trapping them in a
matrix that prevents the aggregates from precipitating out of solution53 . Stability of the MRSw at
370 C may be able to be improved by adding PEG as a linker when attaching the antibodies to the
surface of the MRSw 54 or by adding hydrophobic mutations or disulfide bonds to the antibody55
Reversible MRSw aggregation is another important direction for future work, since this would
allow quantitative measurements of the current state of a solid tumor, instead of only cumulative
measurements of past device exposure. Yibo Ling, a current graduate student in the Cima group,
is working on developing reversible MRSw.
8.2.4 In Vitro Device-Based Sensing
Future studies should be performed to determine the cause of the gradual increase in T2
observed in the devices placed in hCG solutions. Particle size data could be used to determine if
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the increase in T2 is caused by aggregates growing so large that they precipitate out of solution.
This would require the volume of the reservoirs to be doubled, since the current devices do not
hold enough MRSw solution for particle sizing. In vitro sensing experiments with matrix
stabilization of the MRSw should be performed if aggregate precipitation is found to be a
problem. The gradual increase in T2 is most likely caused by thermal degradation of either the
antibody or the link between the antibody and the nanoparticle, and the techniques described
above (Section 8.2.3) may sufficiently address this problem.
8.2.5 In Vivo Device-Based Sensing
Long term use of implanted sensing devices will require demonstration of in vivo stability
for periods exceeding one month. Future studies in a larger animal model will test the correlation
between local hCG concentrations from repeated needle biopsy with each MRI measurement. In
vivo device-based sensing of chemotherapeutic agents or tumor metabolites should also be
performed, to demonstrate use of the sensing device in a wide range of clinical applications.
Future studies that demonstrate in vivo sensing of multiple analytes with a single device would
also increase potential clinical applications for the device.
8.2.6 Polymer Microchipfor Drug Delivery
The preliminary in vitro studies in this thesis should be followed up with in vivo release
studies to demonstrate reliable performance of the injectable format after implantation through a
large bore needle. In vivo leak tests with fully resorbable devices should also be performed. A
fully resorbable, syringe-injectable device will be useful in delivering chemotherapeutic agents
to inoperable tumors.
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